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EVERYBODY HAS IT BUT NO ONE KNOWS MUCH ABOUT IT: HOW PATIENT-PROVIDER COMMUNICATION
& HPV KNOWLEDGE IMPACT THE LIVED EXPERIENCE OF HAVING HPV

by

KELSEY SCHWARZ

Under the Direction of Wendy Simonds, PhD

ABSTRACT
Human Papillomavirus (HPV) is the most prevalent sexually transmitted infection in the United
States. Many individuals, however, are misinformed about key aspects of the STI, negatively view the
disease and those infected with it, and do not use preventive methods to protect themselves and others
from transmission. For this study, I used in-person, semi-structured interviews to examine HPV
knowledge among those with HPV and how this knowledge impacted individuals’ emotional state upon
diagnosis. I also analyzed feelings of stigma among individuals with HPV and how these feelings and HPV
knowledge impacted individuals’ motivations to disclose their status to others. I also examined status
disclosure and sexual behavior among those with HPV and how HPV transmission knowledge impacted
motivations and intentions to participate in prevention behaviors. I found that post-diagnosis many
individuals were ill-informed about HPV transmission, dormancy, prevalence, clearance, impact on men,
and association with cervical cancer. I also found that post-diagnosis many individuals were anxious and
upset about their positive status and felt judged by some individuals in their lives. Confronting and
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internalizing this stigma impacted how and why they disclosed and withheld their positive HPV status. I
also found that few individuals with HPV disclosed their status to all at-risk sex partners or used barrier
methods consistently during sex. These findings suggest that practitioners’ messages and sexual
education about HPV are inadequate. More work is needed to facilitate effective and empathetic
patient-provider communication and HPV education that includes status disclosure and use of all barrier
methods. These findings also suggest that the culture around HPV needs to change so that individuals
with a positive status no longer undergo undue stress and can openly educate others about the STI.

INDEX WORDS: HPV, Stigma, Disclosure, Condoms, HPV knowledge, Transmission, STI Prevention
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1
1.1

INTRODUCTION

OVERVIEW OF ISSUE
Human Papillomavirus (HPV), a sexually transmitted infection, is a highly prevalent disease

(Brewer and Fazekas 2007; CDC 2017a; McCaffery et al. 2004; McCaffery et al. 2006; Nan 2012; Waller
et al. 2007b). It is, in fact, so common that nearly all sexually active individuals will contract at least one
type of HPV during their lifetime (Braun and Phoun 2010; CDC 2017a). Approximately 79 million
Americans are infected with HPV, with 14 million becoming newly infected annually (CDC 2017a). There
are over 100 types of HPV and, although most HPV infections are asymptomatic and transient (usually
clearing within two year), other HPV infection types can cause genital warts and/or lead to cervical,
vaginal, vulvar, penile, anal, and throat cancer in men and women (CDC 2016; CDC 2017a).
HPV is the primary cause of cervical cancer in the U.S. (Nan 2012). Out of the 100+ infections of
HPV, HPV16 and HPV18 are associated with the majority of cervical cancer cases (CDC 2013; Polzer and
Knabe 2012). In the United States, 3,700 women die from this type of cancer each year (2.3/100,000
death rate for cervical cancer) (Connell and Hunt 2010; Grantham et al. 2011; USCSWG 2014). In other
words, a woman not vaccinated against HPV has a 1 percent lifetime risk of developing cervical cancer
(Chapman 2010). The cervical cancer incidence and death rates are higher among Latina and Black
women (10.2/100,000 and 9.4/100,000 respectively; 2.8/100,000 and 4.1/100,000 respectively)
compared to White women (7.8/100,000 and 2.1/100,000) (CDC 2014) in the United States. Anal, head,
neck, penile, vaginal, and vulvar cancers, although rare, are also associated with high-risk HPV (CDC
2017c; ASHA 2018). Over 80% of anal cancers, 70% of head and neck cancers, 60% of penile cancers, and
70% of vaginal and vulvar cancers in the United States are associated with high-risk HPV (CDC 2017c;
ASHA 2018).
Individuals tend to be more aware of HPV’s link to cervical cancer than to other cancers;
however, 38% of Americans are unsure or do not know that HPV causes cervical cancer (Blake et al

2

2015). Even individuals who are knowledgeable about HPV’s link to cervical cancer tend to be unaware
that it is transient in nature and can resolve on its own within a few years (Gerend and Magloire 2008;
Sandfort and Pleasant 2009; Ratanasiripong et al. 2013; Blake et al. 2015). Many Americans are unaware
of the highly prevalent and easily transmittable nature of HPV and do not perceive themselves as at risk
(Blake et al. 2015; Gerend and Magloire 2008; Sandfort and Pleasant 2009; Ratanasiripog et al. 2013).
Nearly 70% of Americans are aware of the HPV vaccine (Blacke et al. 2015). The HPV vaccine
protects against persistent infection of HPV subtypes associated with cancers and anogenital warts
(Rothman 2009; Brelsford 2011). According to clinical trials, the vaccine prevents 90-100% of new high
risk HPV infections among women (aged 15-26) not infected with HPV at time of vaccination (Herrero et
al. 2015). In June of 2006, the HPV vaccine was approved and recommended for girls aged 11-26
(allowing 9 and 10-year-old girls to be eligible for vaccine) (Braun and Phoun 2010; CDC 2011; Connell
and Hunt 2010; Shefer et al. 2008; Wailoo et al. 2010). Vaccinations for boys and men aged 9-26 are
now recommended due to the role they play in transmitting HPV, as well as their increased risk for
cancer (anal, penile, neck), genital warts, and recurrent respiratory papillomatosis (tumors in the air
passages) when infected with HPV, specifically types 6, 11, and 16 (Anic et al. 2011; Dunne et al. 2006;
Elbasha and Dasbach 2010).
HPV vaccination intention is lower among older adolescents and college age women. The most
commonly cited barriers to vaccine intent among college age women were: vaccine safety concerns, side
effects, insurance issues, cost, and low perceived risk (Patel et al. 2012). Among older adolescents and
young adults, those more likely to receive the HPV vaccine are white, insured, 18 to 20 year old women
(Laz et al. 2013). The most commonly cited barriers to vaccine intent and uptake among 18-26 year old
women were: vaccine safety concerns, side effects, insurance issues, cost, low perceived risk, and belief
they were too old to receive the vaccine (Laz et al. 2013; Patel et al. 2012). According to the CDC, the
vaccine is not recommended for women over the age of 26 because it offered limited protection against
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HPV-related diseases in clinical trials due to the fact that most women had already been exposed to one
or more HPV strains in their late teens or early twenties (CDC 2017d). However, research suggests that
the vaccine may be beneficial to older women, even those who are HPV positive. In fact, previously
infected individuals may benefit from vaccination by increasing antibodies and thus helping individuals
clear HPV more quickly and prevent re-infection (Muderspach et al. 2000; Scherer et al. 2016).

1.2

THEORETICAL BACKGROUND
In my dissertation, I sought to reveal the stories of individuals with HPV, as they discuss their

experiences, understandings, and interpretations of living with HPV. Specifically, I aimed to analyze the
connections between HPV knowledge and health literacy after diagnosis, patient-provider relationships,
perceived stigma, disclosure, and sexual behavior. In order to highlight these issues, I relied on the
following theoretical frameworks: stigma, health literacy, patient-provider communication model, and
the information, motivation, behavior model.
1.2.1

Health Literacy
Patients are encouraged to be active and informed health care consumers (Parker 2010, Street

& Epstein 2008). To do so, they must have a high level of health literacy, defined as the “degree to which
an individual has the capacity to obtain, communicate, process, and understand basic health
information and services to make appropriate health decisions” (CDC 2016b: n.p.). Patients with high
health literacy are capable of finding health information and services, communicating their needs,
processing meanings of information, understanding choices and consequences, and deciding what
services meet their need (CDC 2016b). To aid in the development of health literacy, providers should
help patients find information and services, communicate about health and healthcare, process patient
questions and preferences, understand how to provide useful information, and decide what information
and services are best for specific situations (CDC 2016b). Level of HPV health literacy is often related to
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age, gender, socioeconomic status and race (Kutner 2006). According to research, young, white,
educated women are more knowledgeable about HPV compared to men, the elderly, individuals with no
college education, and women from racial and ethnic minority groups (Blake et al. 2015; Gerend and
Magloire 2008; Gerend and Shepherd 2011; Holcomb et al. 2004; Jain et al. 2009; Reimer et al. 2014;
Pruitt et al. 2005; Sandfort and Pleasant 2009; Tiro et al. 2007).

1.2.2

Patient-Provider Communication
Individuals who feel they have a strong relationship with their doctor, compared to those who

do not, can have improved health because they are more satisfied, more likely to heed doctors’
recommendations, and are more committed to treatment plans (Fuertes et al 2007). Patients would
prefer to have providers who are informative, emotionally supportive, and with whom they share
mutual trust, respect, and engagement (Aelbrecht et al. 2014; Mazzi et al. 2015; Fuertes et al 2007;
Fuertes et al. 2016). By openly communicating with patients, doctors can better understand patients’
health problems, answer patients’ questions, and heighten patients’ sense of control over their
diagnoses (Iwamitsu et al 2003; Schofield et al. 2003; Street & Epstein 2008).
Most women diagnosed with HPV tend to have many unanswered questions about their
diagnosis because of the impersonal ways in which they were informed of their status (Harvey-Knowles
and Kosenko 2012). Research indicates that most women do not fully understand HPV upon initial
diagnosis because they are shocked by their diagnosis and lack the mental clarity to ask their doctor for
details about HPV (Bertram and Magnussen 2008; Kosenko et al. 2014). Women also report that they
receive confusing information from their doctors at time of diagnosis (Daley et al. 2008). Specifically,
recently diagnosed individuals are confused about the symptoms, impact on fertility, treatment options,
recommended lifestyle changes, impact on male sexual partners, how HPV differs from other STIs, which
type of HPV they have, and how low-risk HPV differs from high-risk HPV (Bertram and Magnussen 2008;
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Daley et al. 2008; Perrin et al. 2006). This lack of knowledge often occurred when health care providers
use excessive medical jargon, allocate insufficient time to explain the diagnosis, seem insensitive to their
patients, and lack an established patient-provider relationship (Bertram and Magnussen 2008).
1.2.3

Theories of Stigma
A less desirable attribute than one stereotypically assigned to persons of the same category is

known as a “stigma” (Goffman 1963:3). Stigmas can be caused by character flaws, which are personality
traits that deviate from those socially accepted or by physical deformities (Goffman 1963). Stigmatized
individuals are perceived as dangerous to societal norms (Goffman 1963). Society often views women
who stray from the societal norms of female chastity and purity as deviant, morally corrupt,
irresponsible, unclean, and promiscuous (East et al. 2012; Nack 2008). Therefore, they possess a
character stigma and risk negative judgment from others (Nack 2008). According to symbolic
interactionists, individuals incorporate others’ evaluations of them when self-evaluating (Nack 2008:65).
Women with HPV often feel embarrassed about their diagnosis and refer to themselves as “unclean,
“dirty”, “cheap”, “gross” (Daley et al. 2008; East et al. 2012, 17; Nack 2008).
When an individual’s dissimilarity is not obvious upon first meeting, they have a hidden
“discreditable stigma,” and they must determine what to display or who to tell (Goffman 1963:42).
According to Goffman, most individuals will intentionally pass if given the opportunity (1963). Women
with HPV often choose not to disclose their stigma to others because they fear rejection from their
friends, family, and sexual partners (Nack 2008:91). Individuals with a discreditable stigma may choose,
however, to disclose their discreditable attribute to others as a form of “stigma management” (Breitkopf
2004; Goffman 1963:100). Often, a discreditable person will reveal their shameful attribute to a few key
individuals and then rely on those individuals for support (Goffman 1963). Many women disclose in
order to gain the support, sympathy, and acceptance from close friends and family members (Lee and
Craft 2002; Nack 2008:98).
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More recent research on stigma, among individuals with STIs, draws on the Berger et al.’s HIV
Stigma Scale. According to Berger et al., perceived stigma occurs in the context of (1) one’s perception
of society’s attitudes toward a person with HIV and (2) one’s personal knowledge of being HIV positive
(Berger et al. 2001). This perceived stigma can lead to a mal-adjusted sense of self , attempts to control
who knows about one’s status, and even avoidance of potentially stigmatizing social situations (Berger
et al. 2001). The HIV Stigma Scale evaluates personalized stigma, which relates to experiences and fears
of rejection; disclosure concerns, related to controlling who knows their positive status; negative selfimage, related to shame and feeling like a bad person; and concerns with public attitudes, which relates
to fear that larger society will judge a person with a positive status (Barnack-Tavlaris et al. 2016; Berger
et al. 2001). Using this framework, HPV researchers have found that individuals with HPV most
commonly cite feeling negative self-image stigma, whereby they feel dirty and disgusted with
themselves for having HPV (Barnack-Tavlaris et al. 2016). Personalized stigma was also commonly felt by
individuals with HPV, who worried that others would not understand their situation and reject them
(Barnack-Tavlaris et al. 2016). Fewer people were concerned about disclosure, but those who limited
their disclosure were worried about sexual rejection (Barnack-Tavlaris et al. 2016). Researchers found
that individuals with HPV were less affected by public attitude compared to all other types of stigma
(Barnack-Tavlaris et al. 2016).
Attribution theorists posit that public attitude stigma impacts individuals more if they may be
blamed for their serious illness (Lebel and Devins 2008; Weiner, Perry and Magnusson 1988). If a person
participates in voluntary, avoidable, risky behavior that leads to their illness, larger society may view
them negatively (Lebel and Devins 2008; Weiner, Perry and Magnusson 1988). Conversely, if an
individual’s illness is deemed to be unavoidable by larger society they are often accepted and even
pitied (Lebel and Devins 2008; Weiner, Perry and Magnusson 1988). Researchers found, when
comparing the stigma felt by individuals with HIV compared to those with cancer, those with HIV felt
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greater stigma which was, in part, due to HIV patients being viewed as responsible for their diagnosis
(Fife and Wright 2000). Research specific to cancer-related stigma indicates the level of stigma and
blame is associated with type of cancer. They found that blame is more often attributed to women with
cervical cancer than to individuals with cancers unrelated to lifestyle choices, such as leukemia, breast,
or bowel cancer (Marlow et al. 2010, 1802). Due to the fact that the large majority of cervical cancer
cases are linked to high-risk HPV and HPV is acquired through skin-to-skin, oral, vaginal, and anal sexual
contact, public opinion of individuals with HPV may be negative, as it is for individuals with HIV.
Research indicates that women, specifically, with HPV are often viewed as deviant and irresponsible
(East et al. 2012; Nack 2008) and may, therefore, feel more stigma than individuals with cancer whose
behavior may not have contributed to their diagnosis (Lebel and Devins 2008).
1.2.4

Information, Motivation, Behavior Model
According to the “information, motivation, behavior” (IMB) theoretical model, STI prevention

techniques are used by individuals who are well informed, perceive themselves to be at risk, are
motivated to change their risky behavior, and feel capable of using prevention strategies (Bahrami and
Zarani 2015; St. Lawrence and Fortenberry 2007). In order to participate in STI prevention behavior, they
need to be knowledgeable about STI transmission and prevention methods (Fisher and Fisher 1992; St.
Lawrence and Fortenberry 2007). HPV prevention methods include status disclosure to partners and
consistent use of barrier methods, such as condoms and dental dams. According to past research, much
of the general population is unaware of their risk of acquiring and transmitting HPV (Blake et al. 2015;
Gerend and Magloire 2008; Sandfort and Pleasant 2009; Ratanasiripog et al. 2013). Although most of
the general public is aware that HPV is an STI, many do not know that it is linked to genital warts and can
be transmitted through skin-to-skin contact (Gerend and Magloire 2008; Sandfort and Pleasant 2009).
Many individuals are also unaware that STI disclosure is a component of safer sex practices (Luchetti
2009).
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Informed individuals must be motivated to act on their knowledge and change their risky
behavior to preventive behaviors (Fisher and Fisher 1992; St. Lawrence and Fortenberry 2007). One’s
perceived susceptibility to risk and adherence to social norms surrounding prevention techniques are
key components to motivation (Fisher and Fisher 1992). Consistent condom use is associated with
perceived risk to STIs (Bryan et al. 1997). However, many people often do not perceive themselves at
risk for HPV (Gerend and Magloire 2008; Sandfort and Pleasant 2009; Ratanasiripong et al. 2013; Blake
et al. 2015). Individuals must also have the skills to perform the recommended preventive behaviors (St.
Lawrence and Fortenberry 2007). For prevention of HPV transmission, these skills include: obtaining a
vaccine, correct condom use, sexual communication, condom negotiation, and a sense of self-efficacy
(Fisher and Fisher 1992). For women, condom use self-efficacy involves agency over sexual
communication and negotiation with partners (Artistico et al. 2014; French and Holland 2011). Women
who perceive themselves to have less decision-making power in their relationship are less likely to
report consistent condom use (Pulerwitz et al. 2002).

1.3

METHODS
For this study, I employed purposive, facility-based sampling and snowball sampling. I utilized

key locations to find study participants, such the health clinic at a large public university in the
Southeastern United States and multiple privately-operated gynecological clinics around a large
metropolitan area in the Southeastern United States. I also posted flyers around two major universities,
high-traffic pedestrian areas, and throughout diverse neighborhoods. Additionally, I gained entry into
online support groups for individuals with HPV1 to recruit group members for my study. I displayed and
distributed flyers at the recruitment facilities. Multiple versions of the flyer were distributed with

1

http://www.dailystrength.org/c/HPV/support-group; http://hpvsupport.com/phpBB3/;
http://www.mdjunction.com/hpv; http://hpv.supportgroups.com/; http://www.hpvhope.com/support.html;
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various photos of young girls and women from different racial and ethnic groups on them in order to
appeal to a diverse group of potential participants. Each flyer contained tear-off tabs so that interested
parties could easily obtain my contact information. Additionally, each flyer included a Quick Response
code that linked smartphone users to my online eligibility form. This eligibility form required users to
enter their age and HPV status and then, if eligible and interested in participating, their contact
information was automatically sent to me.

1.3.1

Sample Demographics

My participants included 23 women of various ages2. Six were in their 20s, eleven in their 30s, three
in their 40s, two in their 50s, and one over 60 years old. Age at diagnosis varied with three receiving
there HPV diagnosis at age 19, seven receiving it in their early 20s, six in their late 20s, three in their
early 30s, one at age 45, and one at age 60. My sample was a highly educated group, with 10 of my
participants having obtained a graduate degree, four in graduate school at the time of interview, six
obtaining a terminal Bachelor’s degree, one currently in undergraduate school at the time of interview,
one having had some college education, and one having a GED as highest level of education. The
majority of my participants (73.9%) were white, 21.7% were black, and 4.35% were multiracial. Ten of
my participants were single at the time of interview, 8 were in a committed relationship, and 5 were
legally married. In terms of gender identity, 22 of my participants identified as women and one
identified as gender queer. In terms of sexual orientation, 18 classified themselves as heterosexual, one
as lesbian, and four as bisexual.

2

My sample originally included 25 individuals, but after the interview, I determined two no longer qualified to be
included in my sample due to their type of HPV. Both of those original participants had HPV that manifested as skin
warts on the hands and feet – a condition that is not considered a sexually transmitted infection and is not related
to reproductive issues or cancers. Therefore, the numbers next to each quote coincide with the participants’
original interview number (1-25).

10

1.4

CURRENT STUDY
Past HPV research has mainly focused on knowledge, awareness, and attitudes regarding the

illness and vaccine (see: Constantine and Jerman 2007, Dempsey et al. 2006, Gerend and Magloire 2008,
Holcomb et al. 2004, Pruitt et al. 2005). Research that has centered on women’s experiences related to
STIs is often related to genital herpes (see: Lee and Craft 2002), or a multitude of STIs including HPV,
genital herpes, and chlamydia (see East et al. 2012, Nack 2000). Major HPV-specific research studies
have been conducted outside of the United States (see: McCaffery et al. 2004, McCaffery et al. 2006,
Waller et al. 2007a) and are often survey based (see: McCaffery et al. 2004, Waller et al. 2007a). Due to
the fact that the CDC recommendation of the HPV vaccine was fairly recent, past research on HPV (see:
Nack 2002, Nack 2008, Perrin et al. 2006) did not analyze women’s lived experience in relation to the
vaccine. More recent scholarship related to HPV has instead focused on the influence of social support
for Women with HPV (see: Kosenko et al. 2012).
The current study adds to the field of research by exploring the lived experience of individuals
who have been diagnosed with HPV through semi-structured interviews. Through detailed accounts of
individuals’ experiences with having HPV, I was able to analyze how individuals with HPV felt about
themselves, what they knew about their diagnosis, who they told, and how it impacted their sexual
behavior. This work contributes to existing research on HPV in the United States and adds to current
research on health literacy, patient-provider communication, and STI prevention.
The following chapters highlight the process from diagnosis to post-diagnosis emotional state to
disclosure to friends, family, and sexual partners to sexual behavior choices post-diagnosis. A major
theme throughout these chapters is HPV knowledge. Many individuals with HPV who were misinformed
about HPV prevalence, transmission, consequences for partners, clearance and dormancy experienced
undue stress, internalized stigma, put themselves at risk for re-infection and put their sex partners at
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risk for contracting HPV. As I posit in the following chapters, informative, emotionally supportive doctors
play a vital role in educating individuals at diagnosis and the general public on basic facts related to HPV.
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2

“They Just Railroaded Past It Like It Was Not a Big Deal”: How Providers Impact Patient HPV
Knowledge and Experience

2.1

ABSTRACT
Human Papillomavirus (HPV) is the most prevalent sexually transmitted infection in the United

States, however, health literacy around HPV is relatively low. Many individuals are misinformed about
key aspects of HPV. This study uses in-person, semi-structured interviews to examine HPV knowledge
among those with HPV. It also analyzes how this knowledge impacted individuals’ emotional state upon
diagnosis. The study found that post-diagnosis many individuals were ill-informed about HPV
transmission, dormancy, prevalence, clearance, and association with cervical cancer. These findings
suggest that practitioners’ messages about HPV are inadequate and more work is needed to facilitate
effective and empathetic patient-provider communication.

2.2

INTRODUCTION
Human Papillomavirus (HPV) is transmitted most commonly through sexual contact, such as

vaginal, anal, oral sex, and intimate skin-to-skin contact (Moscicki 2005). It is the most prevalent sexually
transmitted infection in the U.S. (CDC 2017a). According to 2016 data, nearly 79 million Americans are
infected with HPV, with 14 million becoming newly infected annually (CDC 2017a). Although increased
incidence of HPV has long been associated with greater number of sexual partners and “risky” sexual
behavior (e.g., multiple partners, unprotected sex), according to recent data, many women acquire HPV
within the first few months (2.6 month median) of their first sexual relationship (Collins et al. 2002). In
fact, Collins et al. suggest that “perhaps cervical human papillomavirus infection should now be
considered an inevitable consequence of sexual activity” (2002:98). Despite heightened vaccine
messaging (Abdelmutti and Hoffman-Goetz 2009; Mamo et al. 2010), 32% of Americans have never
heard of HPV; 31% have never heard of the HPV vaccine; nearly 38% are unsure or do not know that
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HPV causes cervical cancer; 43% do not know that HPV was a sexually transmitted infection; and 95% do
not know that HPV often clears3 from the body without treatment (Blake et al. 2015).
Over the past few decades, the United States health care system has transitioned. Previously,
patients were passive participants, now they are encouraged to be active and informed health care
consumers (Parker 2010, Street & Epstein 2008). Despite the health care industry’s promotion of patient
empowerment, misinformation and misunderstanding are common, therefore researchers and health
practitioners “must pay attention to how patients access, understand, and use health information
provided to them to promote, protect, and manage their health” (Parker 2010:29). Health literacy is the
“degree to which an individual has the capacity to obtain, communicate, process, and understand basic
health information and services to make appropriate health decisions” (CDC 2016b: n.p.). Patient health
literacy skills include: finding health information and services, communicating their needs, processing
meanings of information, understanding choices and consequences, and deciding what services meet
their need (CDC 2016b). Provider health literacy skills include: helping patients find information and
services, communicating about health and healthcare, process patient questions and preferences,
understanding how to provide useful information, and deciding what information and services are best
for specific situations (CDC 2016b). Health literacy is a basic tenet of public health promotion and a
critical effort of the United States Department of Health and Human Services (U.S. Dept. of Health and
Human Services 2010).
Level of HPV health literacy is often related to age, gender, socioeconomic status and race
(Kutner 2006). Americans, aged under 65 are more likely to have heard of HPV, the vaccine, and to know
that HPV can cause cervical cancer, compared to Americans over the age of 65 (Blake et al. 2015). White
women are more likely to be aware of HPV and the vaccine, have greater knowledge of HPV, and to
have been diagnosed with HPV, compared to women of other racial and ethnic groups (Blake et al. 2015;
3

According to research, HPV often clears from the body because of the host’s immune response (Moscicki et al.
2006). Most HPV infections clear within 2 years (CDC 2013).
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Gerend and Shepherd 2011; Jain et al. 2009; Reimer et al. 2014; Tiro et al. 2007). HPV health literacy,
specifically awareness of and knowledge about HPV, is positively associated with level of education
(Blake et al. 2015; Holcomb et al. 2004; Jain et al. 2009; Pruitt et al. 2005; Tiro et al. 2007). Americans
with a college education are more likely than those with a high school degree to have heard of HPV and
the HPV vaccine, to know the link between HPV and cervical cancer, and to know that HPV is a sexually
transmitted infection (Blake et al. 2015). While many college students are knowledgeable about HPV’s
link to cervical cancer, they tend to be unaware of the link to genital warts; that HPV can be transmitted
skin-to-skin; that HPV is transient in nature and can resolve on its own; that HPV is highly prevalent; and
that most women with HPV will never develop cervical cancer (Gerend and Magloire 2008; Sandfort and
Pleasant 2009). College students also often do not perceive themselves as at risk for HPV (Gerend and
Magloire 2008). A more recent study on a racially and ethnically diverse group of women college
students found both vaccinated and non-vaccinated women are unaware of the disease’s prevalence,
risks of transmitting HPV, and that HPV can cause genital warts (Ratanasiripong et al. 2013).
2.3
2.3.1

THEORY
Doctor Communication Regarding HPV
Researchers have analyzed patient-provider interactions since the 1950s. These interactions

range from the paternalistic model of the 1950s, where the patient was a passive actor and the doctor
maintained control, to the 1970s’ consumerist model, where patients exercised greater control than
their doctors (Street & Epstein 2008). Recent research indicates that patients prefer their relationship
with their doctor to be one with mutual trust, respect, and engagement (Fuertes et al 2007; Fuertes et
al. 2016). They prefer to have providers who are informative, emotionally supportive, empathetic,
respectful, competent, and pleasant (Aelbrecht et al. 2014; Mazzi et al. 2015). Individuals who feel they
have a strong relationship with their doctor, compared to those who do not, can have improved health
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because they are more satisfied, more likely to heed doctors’ recommendations, and are more
committed to treatment plans (Fuertes et al 2007).
Squier developed the model of “empathetic understanding,” in which he posited that doctors
could better understand health problems through open communication and labeling of feelings and
sensations (Street & Epstein 2008). However, doctors are not often comfortable discussing patients’
distress because emotional detachment to patients is favored in the Western medical field (Kerasidou
and Horn 2016). Additionally, some patients refrain from expressing emotion upon diagnosis of a
potentially life-threatening disease, which can lead to heightened anxiety and depression (Iwamitsu et
al. 2003). According to researchers, encouraging patients’ emotional expression at diagnosis, being
reassuring, clearly communicating disease-specific information, and answering patients’ questions the
same day can give patients a better sense of control and diminish their distress (Iwamitsu et al 2003;
Schofield et al. 2003).
In-depth interview analysis demonstrates that general practitioners and nurse practitioners do
not widely discuss HPV with their women patients (McSherry et al. 2012). Research suggests that among
women receiving routine Papanicolaou (Pap) tests, rarely do doctors discuss the topic of HPV (Cermak,
et al. 2010). In fact, women often report that their doctors neglected to mention HPV associated risks,
HPV prevention, and the HPV vaccine during their Pap test appointments (Cermak, et al. 2010). Women
undergoing routine Pap tests rarely demonstrate an understanding of why the test is being performed
and what normal and abnormal results indicate (Mays et al. 2000).
Most women diagnosed with HPV are informed by their clinical staff by phone, letter, or email
(Harvey-Knowles and Kosenko 2012; McCree et al. 2010). They tend to have many unanswered
questions about their diagnosis, because of the impersonal ways in which they news is delivered
(Harvey-Knowles and Kosenko 2012). Researchers posit that most women do not fully understand HPV
upon initial diagnosis (Bertram and Magnussen 2008; Kosenko et al. 2014). Upon initial diagnosis,
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women are often shocked and lack the mental clarity to ask their doctor details about HPV (Kosenko et
al. 2014). Patients may express embarrassment, fear, confusion, anger, and concern about cancer and
fertility (Daley et al. 2008; Diaz 2013; Nack 2008). Upon diagnosis, women with HPV may feel “dirty,”
“gross,” or “unclean” (East et al. 2012:17; Nack 2008:66). They are often confused about the symptoms,
impact on fertility, treatment options, recommended lifestyle changes, impact on male sexual partners,
and how HPV differs from other STIs (Bertram and Magnussen 2008; Perrin et al. 2006).
Post-diagnosis surveys conducted across four states indicate that women are incorrect or
unsure about: how many types of HPV exist; that it is not a sex-specific infection; that a vaccine can
prevent it; and that it is transient in nature and can clear (McCree et al. 2010). Research also indicates
that women with HPV often lack knowledge about the sexual transmission and high prevalence of HPV
(Barnack-Tavlaris et al. 2016; Bertram and Magnussen 2008; Sharpe et al. 2006). Other misconceptions
about HPV, among women with HPV, are that it is a bacterial infection similar to a yeast infection or that
it is a permanent illness (Barnack-Tavlaris et al. 2016; Bertram and Magnussen 2008; Daley et al. 2008).
Women with HPV often understand that there is an association between abnormal Pap test results and
cancer (Tiro et al. 2007; Sharpe et al. 2006), although few specify cervical cancer (Sharpe et al. 2006).
They are less likely to associate abnormal Pap tests with HPV (Sharpe et al. 2006). Prior to HPV+
diagnosis, many women with abnormal Pap tests report little concern about their health at the time of
their first abnormal Pap test (Sharpe et al. 2006). These women often are unsure or incorrect about
which type of HPV they have, and often confuse low-risk HPV with high-risk HPV (Bertram and
Magnussen 2008; Daley et al. 2008).
Women often report that they receive confusing information from their doctors at time of
diagnosis, formulate new questions after leaving the doctor’s office, and are too upset at time of
diagnosis to understand their doctor (Daley et al. 2008). Women often seek out HPV information online
post-diagnosis (Harvey-Knowles and Kosenko 2012). Women who are diagnosed with HPV and are then
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scheduled to have a colposcopy4 also lack knowledge about the infection’s transmission, treatment,
symptoms, and association with cervical cancer (Pruitt et al. 2005). Women with HPV have
recommended, in a research study, that doctors discuss the prevalence of HPV and do not solely focus
on discussing their condition as potentially cancerous (Bertram and Magnussen 2008).
When given educational materials on HPV, women are less likely to feel anxious about testing
and be less concerned if they test positive, compared to before reviewing the educational materials
(Papa et al. 2009). Despite some reports of helpful and communicative doctors, women recently
diagnosed with HPV often lack information about the infection (Bertram and Magnussen 2008; Kosenko
et al. 2014; Perrin et al. 2006; Sharpe et al. 2006). This lack of knowledge often occurred when health
care providers used excessive medical jargon, allocated insufficient time to explain the diagnosis,
seemed insensitive to their patients, and lacked an established patient-provider relationship (Bertram
and Magnussen 2008).

2.4

CURRENT STUDY
Due to the fact that many individuals are still unaware of HPV, its link to cervical cancer, and the

HPV vaccine, researchers highlight the need for effective patient-provider communication about this
topic (Blake et al. 2015; Smith et al. 2015). Through my research, I sought to discover whether
individuals with HPV were knowledgeable about the infection prior to and after their own diagnosis and
how their knowledge of HPV influenced their feelings upon diagnosis.
Due to health practitioners’ noted poor communication about the STI, I sought to discover
whether individuals diagnosed with HPV were knowledgeable about the infection prior to and after

4

A colposcopy is often recommended after an abnormal pap result. During this procedure, a health care provider
examines the cervix through a colposcope and, if need be, performs a biopsy of the cervix for laboratory testing
(Johns Hopkins n.d.).
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diagnosis. Through my research, I also sought to understand how those diagnosed with HPV felt about
themselves after diagnosis and how their knowledge of HPV influenced these feelings.

2.5

METHODS
I recruited my participants via advertisements (flyers) displayed and distributed at the

recruitment facilities. This discreet recruitment method is commonly used among STI researchers in
order to avoid embarrassment of participants (see: Kosenko et al. 2012; East et al. 2012). Multiple
versions of the flyer were disseminated with various photos of young girls and women from different
racial and ethnic groups on them in order to appeal to a diverse group of potential participants. Each
flyer contained tear-off tabs so that interested parties could easily obtain my contact information.
Additionally, each flyer included a Quick Response code. Quick Response codes are an increasingly
popular advertisement tool that can be scanned and read by smartphones (Shin, Jung, and Chang 2012).
The flyers contained a unique Quick Response code that linked smartphone users to my online eligibility
form. This eligibility form required users to enter their age and HPV status and then, if eligible and
interested in participating, their contact information was automatically sent to me.
Due to the fact that individuals with STIs qualify as a hard-to-reach population and recruitment
can be difficult (Dixon-Woods et al. 2001; Nack 2008), I employed purposive, facility-based sampling and
snowball sampling. I utilized key locations to find study participants (Magnani et al. 2005), such the
health clinic at a large public university in the Southeastern United States and multiple privatelyoperated gynecological clinics around a large metropolitan area in the Southeastern United States.
Commonly cited barriers to STI screenings include cost, privacy, language barriers, and perceived
discrimination at the clinical site (Tilson et al. 2004). Therefore, I chose to include clinics that offer free
or low-cost STI screening services to English and non-English speakers and that abide by anti—
discrimination laws specific to patient admission and treatment. I also posted flyers around two major
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universities, high-traffic pedestrian areas, and throughout diverse neighborhoods. Additionally, I gained
entry into online support groups for individuals with HPV5 to recruit group members for my study. In
order to allow for fully informed consent on the part of my subjects, I included accurate and
straightforward information about my research and its purposes.

2.5.1

Sample Demographics

I gave all of my participants pseudonyms to protect their identity. My participants included 23
women of various ages6. Six were in their 20s, eleven in their 30s, three in their 40s, two in their 50s,
and one over 60 years old. Age at diagnosis varied with three receiving there HPV diagnosis at age 19,
seven receiving it in their early 20s, six in their late 20s, three in their early 30s, one at age 45, and one
at age 60. Sixteen of the 23 participants grew up in a two-parent family, three had a single parent, three
had divorced parents and stepparents in the home, and one had divorced parents that never remarried.
Twelve of my participants grew up in the Southeastern United States. Six of my participants grew up in
the Northeast, three grew up in the Midwest, and two grew up outside of the United States. My sample
was a highly educated group, with 10 of my participants having obtained a graduate degree, four in
graduate school at the time of interview, six obtaining a terminal Bachelor’s degree, one currently in
undergraduate school at the time of interview, one having had some college education, and one having
a GED as highest level of education. Regarding occupation, eight worked in health and medicine, four in
education, three in law, three in the arts, one in business administration, one in marketing, one in
plumbing/engineering, and two as current students. The majority of my participants (73.9%) were white,

5

http://www.dailystrength.org/c/HPV/support-group; http://hpvsupport.com/phpBB3/;
http://www.mdjunction.com/hpv; http://hpv.supportgroups.com/; http://www.hpvhope.com/support.html;
6
My sample originally included 25 individuals, but after the interview, I determined two no longer qualified to be
included in my sample due to their type of HPV. Both of those original participants had HPV that manifested as skin
warts on the hands and feet – a condition that is not considered a sexually transmitted infection and is not related
to reproductive issues or cancers. Therefore, the numbers next to each quote coincide with the participants’
original interview number (1-25).
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21.7% were black, and 4.35% were multiracial. Ten of my participants were single at the time of
interview, 8 were in a committed relationship, and 5 were legally married. In terms of gender identity,
22 of my participants identified as women and one identified as gender queer. In terms of sexual
orientation, 18 classified themselves as heterosexual, one as lesbian, and four as bisexual. Fifteen of the
participants resided in the Southeastern U.S. at the time of their interviews, and three lived in the
Northeast, one in the Southwest, two in the West, and two outside of the United States.

2.5.2

Interview Method

Although many past researchers have used surveys to analyze knowledge, awareness,
and attitudes regarding HPV and the vaccine, other researchers find that semi-structured interviews
allow participants to demonstrate meanings attached to their STI diagnosis and personal experiences of
dealing with this new diagnosis (see: Gerend and Magloire 2008; Lee and Craft 2002). Interviews of
HPV+ participants, compared to survey research, are more likely to foster discussion of actual lived
experiences related to diagnosis and living with HPV.
As a feminist interviewer, I was cognizant of my role as a researcher and my potential
source of authority during the interview process (Hesse-Biber 2007). In order to diminish the
hierarchical relationship between researcher and participants, after each interview, I shared relevant
aspects of my own biography (Hesse-Biber 2007) and experience with HPV. I strove to be reflexive and
to consider how my biography, values, and attitudes influenced the research process (DeVault and Gross
2012; Hesse-Biber 2007). As a woman with HPV, throughout the interview and analysis stages, I
reflected on how my attitudes regarding the disease impacted my choice of interview questions and my
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interpretation of participants’ responses (DeVault and Gross 2012). For example, my experience with a
non-empathetic, uninformative doctor motivated me to ask about doctor-patient interactions and
helped me understand the participants’ frustrations with similar experiences.
Interview topics included: how participants felt upon initial diagnosis of HPV, what information
they knew about HPV and the vaccine prior to diagnosis, what information they were given or sought
out about HPV after diagnosis, how their diagnosis impacted them, and how they felt about themselves
post-diagnosis.

2.5.3

Analysis
I conducted, recorded, and transcribed all of the interviews. I imported all transcribed materials

into NVivo and analyzed using a grounded theory approach. I chose this analytic method because it is
well suited for understanding social processes not yet commonly researched (Milliken 2010). And, as
noted above, there have been very few qualitative studies on the lived experiences of individuals with
HPV. From my transcription and pre-analysis coding, I identified a few themes that I wanted to further
investigate related to patient-provider relationships: “patient- provider communication,” “HPV,” and
“HPV vaccine.” I analyzed the transcripts using the triadic coding scheme of open, axial, and selective
coding (LaRossa 2005). During open coding, I identified major themes related to patient-provider
relationships, emotional response to diagnosis, and HPV knowledge, and deciphered what each concept
represented (Lofland et al. 2005; LaRossa 2005). Most participants discussed how they received their
diagnosis and what information their doctor did or did not provide them with at diagnosis. In the
context of their diagnosis, each participant mentioned what they knew about HPV and how they felt
upon initial diagnosis. I then reviewed the concepts for similarities and variations, assigned them to
categories, and identified the most salient categories (Corbin and Strauss 1990). I analyzed patientprovider communication to determine whether or not the doctors were generally informative,
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supportive, and accessible to their patients. I then examined possible relationships between having an
empathetic doctor and one’s experience with the diagnosis of a sexually transmitted infection. I also
analyzed participant HPV knowledge pre- and post-diagnosis to determine what information each one
learned after they were diagnosed with the STI. Finally, I analyzed the participants’ emotional responses
to diagnosis (to determine if they were upset, unsuspecting, or seemingly unaffected by their positive
status) and feelings about themselves post-diagnosis. In the axial coding stage, I analyzed the categories
to determine how and why they differed among the participants, by focusing on the context, strategies,
and consequences associated with each category (Corbin and Strauss 1990; LaRossa 2005). I analyzed
relationships between HPV knowledge post-diagnosis and patient-provider communication. I also
analyzed the relationship between HPV knowledge post-diagnosis and participants’ emotional response
to the diagnosis and how they learned about diagnosis. Finally, I moved on to the selective coding stage
of my analysis, where I decided which categories were most representative of the central argument of
my analysis (Corbin and Strauss 1990; LaRossa 2005). I found the relationships of post-diagnosis
knowledge, how participant was diagnosed, and their emotional response to diagnosis to be most
informative and related to patient-provider communication.

2.6
2.6.1

FINDINGS
Pre-Diagnosis Knowledge
I looked at the impact informative doctors made on their patients’ knowledge of HPV. In order

to access what knowledge each participant gained from their interactions with their doctor, I had to
evaluate what information they knew about HPV prior to their diagnosis. Thirteen of the participants
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already knew basic facts7 about the STI. Six of these individuals knew HPV was medically related to
cancer. One of those participants felt that she would avoid the “really really scary stuff” (Amber) like
cervical cancer because she had been vaccinated against HPV, while another noted that her knowledge
of the link between cancer and HPV also came from vaccine messaging, stating: “I think I knew of it
mostly through the vaccine advertisements. It was something that could cause cancer -- but maybe not
necessarily -- and that there was a vaccine for it, but I had never considered getting it” (Erica). Seven of
the individuals already knew that HPV was highly prevalent before their diagnosis. Most of those
recalled not being scared or upset about their diagnosis because they knew how common HPV was in
the United States. One participant learned about the prevalence because she had a friend diagnosed
earlier and had researched the topic. She said: “I … found out that 90% of women have it at one point in
their life whether or not they are aware of it” (Amber). Six participants explicitly stated that they were
aware that HPV was a sexually transmitted infection before discussing their status with their doctor.
Only two of the participants knew all of these basic HPV facts, four more knew two out of three of these
facts.
Eleven participants were unaware of HPV prevalence, sexual transmission, and cancer
consequences before their diagnosis. Five participants recalled having no knowledge of HPV prediagnosis, revealing: “I didn't know anything about it when I was diagnosed (Emily)” and “I hadn't even
heard of HPV at that time” (Andrea). Two of these participants researched the STI after visiting their
doctor and learning they were HPV positive. One maintained that she “did not feel like she [the nurse]
knew much … so I looked it up myself when I got to the car… right away.” (Janelle) Researching HPV,
however, sometimes caused more anxiety about their diagnosis. For example, one woman, who already
knew HPV basics before diagnosis said: “I looked up stuff on the internet which is always terrifying. I

7

Basic HPV facts, based on past research (Gerend and Shepherd 2011; Sandfort and Pleasant 2009 ), include (1)
genital HPV infection can cause cancer (2) most genital infections clear up on their own (3) most individuals with
HPV are asymptomatic (4) HPV is very prevalent (5) HPV can be transmitted by skin-to-skin contact.
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think I tried to skip WebMD and went to the Mayo clinic… something a little more reliable, but it was
still, like, this causes cancer and you will die…. That is not what I want to hear” (Erica).

2.6.2

Post-Diagnosis Knowledge
Post-diagnosis, nineteen participants knew about prevalence, transmission, dormancy, clearing,

or risk associated with HPV post-diagnosis. The most frequently cited HPV facts were related to
prevalence of the STI. Fifteen participants discussed the high prevalence of HPV. Three of them received
this information upon initial diagnosis (e.g.: “My gynecologist said it was really not that big of a deal so
really don't worry about it... ‘cause 1 in 5 people has it.” [Emily, diagnosed at age 19]), while others
attributed their knowledge to the Garadasil commercials: “I knew more about what was going on… the
prevalence… at that point there were already commercials and stuff for the vaccine which was out by
then (Ashley, diagnosed at age 19).” Two individuals acquired their knowledge of HPV prevalence from
studying the subject: “I have worked in sexual health since, like, 1989 so you know.... I understand that
98% of the world has it (Colleen, diagnosed at age 38)” and “I know a lot about it because I formally
studied reproductive health ... at a conference I went to a presenter said that HPV was biomarker of
sexual activity for our generation (Phoebe, diagnosed at age 20).” Most of these individuals simply
conveyed that they knew it was common or that a “fairly significant proportion of the population has
HPV (Leah, diagnosed at age 22)” and this oftentimes made them feel like their diagnosis was less
worrisome: “Everybody has it. I am just one of everybody (Colleen, diagnosed at age 38).” However,
knowledge about prevalence did not alleviate everyone’s worry about the diagnosis, as one participant
stated: “you know, I judge myself…. I should have been more assertive about using condoms….I know it
[HPV] is really common but I just have a different standard for myself I guess (Whitney, diagnosed at age
45).” One individual felt that her doctor’s message about prevalence was both beneficial and
detrimental: “I think it makes people feel less stigmatized. I think it matters how it is said. Talking about
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the prevalence is different than saying, ‘oh, everyone has it and it is not a problem.” Just because
something is prevalent does not mean it is not a problem or that it does not have negative
consequences (Candace, diagnosed at age 19).”
As stated above, participants also demonstrated knowledge of HPV related to transmission,
dormancy, and clearing. Four individuals explicitly stated that HPV could be transmitted from skin-toskin contact, did not require penetrative sex, and that condoms would not completely protect a person
from contracting it. According to two of these participants: “There is no 100% and I think it is a false
sense of security people do get from using condoms (Riley, diagnosed at age 20)” and “People probably
don't know that HPV is transmitted by skin-to-skin contact, and you can use condoms but it is not just
about covering an orifice. You would have to have sex with a rubber suit on (Colleen, diagnosed at age
38).” One participant explained that this information came from her doctor upon diagnosis: “She
mentioned that the protection of a condom does not always work (Ava, diagnosed at age 22).” Another
individual may have been misinformed by her doctor who told her that “it was sexually transmitted and
I could pass it from cervical to penile contact … that was it (Tiffany, diagnosed at age 31).” Four
participants mentioned that HPV can lie dormant in your body for a period of time. Specifically, they
mentioned: “HPV can come up years after you've had a relationship with someone (Amber, diagnosed at
age 25)”. A different participant actually felt misinformed by her doctor when she found “things [that]
conflicted with what my doctor said…. She was very sure I had gotten it from my current partner and ...
research I did online said it could be dormant (Ava, diagnosed at age 22).” Only two participants stated
that their doctor told them that HPV could clear from a person’s body: “I had HPV and then I had normal
Paps since, and my doctor said that my body must have cleared it - that was the language that he used
(Candace, diagnosed at age 19)” and the doctor “said it is really common; your body will probably clear
it in a couple of years (Carla, diagnosed at age 32).” Two other participants learned about clearance on
their own; one knew about it only after no longer having HPV: “everything after that was fine. They
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never needed to do anything else after…. I think it was just that I am fine... because I had HPV... it
cleared out of my system I want to say within 2 years…. Then I was tested for my yearly the next year. I
was clear of everything and I thought that was weird, but I came to find out that it can come and go out
of your system [clear]. (Ashley, diagnosed at age 19).”
Eight participants mentioned their knowledge about developing cancer from HPV. Some
of these individuals learned that HPV was related to cancer directly from their doctors: “the second
diagnosis, when it was pre-cancerous… I believe they said ‘cervical’... the second time…. My only
concern was if I was going to develop cancer (Leslie, diagnosed at age 22)” and “I just wanted to know if
it [biopsy] would come back as anything…, like, anything important that was going to be leading to
cancer.... That was my biggest concern (Ashley, diagnosed at age 19).” Two participants actually referred
to their diagnosis as “pre-cancer (Leah, diagnosed at age 22).” Three learned this information from the
Gardasil marketing campaign: “Now that I have it I think about cervical cancer ... only because the
commercials are, like, if you have HPV you are more likely to get cervical cancer (Emily, diagnosed at age
19)” and “I think I knew of it mostly through the vaccine advertisements. It was something that could
cause cancer but maybe not necessarily and that there was a vaccine for it (Erica, diagnosed at age 26)”.
Another individual said: “I read a statistic that, like, 90% of cervical cancer is caused by HPV even though
most HPV is perfectly harmless. And reading that for the first time was like, oh I have this thing that
basically you don't get cervical cancer if you don't have [it] (Phoebe, diagnosed at age 20).” One
participant knew about the link between HPV and cancer, but stated that she was more concerned with
infertility as a consequence of the STI: “from what I read the odds of developing cancer are relatively
small, but after having the Loop Electrosurgical Excision Procedure (LEEP)8, the odds of having a
complication from that are small, but something about that was scary to me. Anything that impacts

8

With LEEP, an electric current heated wire loop removes abnormal cells and tissues in the cervix and vagina. The
tissue is then sent to a lab for testing. LEEP is often performed in order to detect cancer of the cervix or vagina
(Johns Hopkins n.d.).
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fertility to me is, like, oh.... I don't know why that is scarier than cancer... but something about it made it
really serious to me (Candace, diagnosed at age 19).”

2.6.3

Comparing Pre- and Post-Diagnosis Knowledge
Although almost all of the participants were informed about at least one aspect of HPV after

their diagnosis, many were not fully informed. Nineteen of the 23 participants remained unaware of the
fact that HPV can lie dormant in a human body for many years and 19 did not know that the body can
clear HPV within a few years of contracting it. Among the individuals who knew about the body’s ability
to clear HPV, only two learned this information from their doctor. Another participant who was aware of
clearance learned this information by reading literature on HPV. Nineteen of the participants also did
not know that HPV could be contracted through skin-to-skin contact and did not require penile-vaginal
or penile-anal penetration. One of the 4 participants who knew about skin-to-skin transmission of HPV
learned this information by working in the STI field, not from her doctor. One participant who knew
about skin-to-skin transmission learned this directly from her doctor and the others were unsure where
this information originally came from stating, “honestly my education may have come from commercials
which is probably bad… but ... yeah it could have been a thing where my doctor mentioned it first… I
don't really remember. I don't think I knew much about it until the time I was about to get the vaccine”
(Carla, diagnosed at age 32). Seven interviewees did not understand that HPV was linked to cancer in
women. Among those who knew about the association between HPV and cancer, four learned this from
their doctor, two learned this through online research, three learned this through the Gardasil
campaign, and the rest were unsure about where they obtained this knowledge. Eight participants
remained unaware of the high prevalence of HPV after their diagnosis. Among those who learned about
the high prevalence of HPV post-diagnosis, three attributed this knowledge to their own research or the
vaccine commercials, rather than their doctor.
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2.6.4

Emotional Impact of Diagnosis
Participants’ emotional responses upon initial HPV diagnosis demonstrate a range of responses,

framed largely in terms of anxiety and worry or lack thereof. Five participants were ambivalent about
their positive diagnosis. One stated: “I wasn't upset because, you know, what can I do about it?” (Carla).
Another related her lack of anxiety surrounding diagnosis to her pre-diagnosis knowledge stating, “I
must have known how common it was because I never got freaked out, really” (Phoebe).” One
participant differentiated between cancer and HPV: “HPV's not really the problem - the problem is the
cancer cells, so while I didn't worry about what was going on with that… I don't know, it didn't seem like
something worth worrying about. Everybody has it, we will just have to deal with it” (Andrea). Another
participant related her reaction to the diagnosis to her personality: “I just thought, it is what it is…. I am
just the type of person…. I don't mope and groan about one thing because there is just so much more
for me to have to worry about” (Tiffany).
Nineteen participants, however, had negative feelings toward their diagnosis. Many of them felt
anxious and scared upon diagnosis. One said: “I was stressed out. It was more confusing... everything
else was fine on the day of my checkup... everything else was fine, I was good ... I NEVER expected to
have an STI just because I play it safe and I haven't had many partners AT ALL. So I was upset. I felt that I
was tainted unfairly” (Kendra). Another stated: “I felt scared ... yeah and nervous about it. There was a
point when I was 20 or something when I had bumps, like, in my vulva and they really looked white and I
got freaked out - I don't remember if that was before or after I found out I had the abnormal cells - but I
remember being terrified by that ... terrified that I had something” (Candace). Other participants stated:
I was concerned. There was nothing they could do… (Katherine),
I was really upset... I cried... I was really afraid... (McKenzie),
I mean I was initially scared and you know (Summer),
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I was mortified... absolutely mortified (Ashley),
I kind of just felt like I was broken (Kaylee),
[I]s it that serious... how quickly can it become serious (Erica).
[I]s it something that is going to kill me (Janelle).
Some were caught off guard by their diagnosis. One participant stated: “I was really surprised to
be honest” (Jessie). Another stated that she “had a shockingly late, surprising diagnosis… I don't
understand how I have HPV now and I haven't for the majority of my life” (Colleen). Others were
ashamed by their diagnosis; saying things like: “I felt dirty and I felt gross … I felt ugly and I did not feel
sexually viable” (Emily), and “I feel ashamed I guess... you know, you are just dirty, kind of” (Whitney).
Some participants felt that their positive HPV status was deserved because they had been “irresponsible
with [my] body” (Amber) in the past or upon diagnosis they thought, “‘Holy Shit! what Bastard had it?’…
I thought, in my own Roman Catholic upbringing as a child…, ‘oh, now I guess you paid for that piece of
ass’” (Theresa).

2.6.5

Emotional Impact of Diagnosis by Type of Diagnosis
Five of the participants received word of their positive status from a nurse or clinic staff

member, not their doctor. The participants who were informed by a nurse commonly felt their
conversations were awkward. All of these participants had negative emotional reactions to their
diagnosis. One participant, who felt ashamed and dirty upon diagnosis, stated: “It was weird because
somebody called me on the phone that was not my regular gynecologist - she was on vacation- so this
stranger called me up and told me about it” (Whitney). One participant who was shocked by her
diagnosis recalled receiving this information over the phone stating: “So the nurse called and said, ‘We
got your test results back and everything looks good, HPV came back positive,’ and she just RAN through
it and I was, like, ‘what?’ and she was ‘your HPV is positive’ and I said ‘how is that possible, I am always
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negative’…. So I said to the nurse, ‘no my doctor needs to call me back immediately and explain these
test results’” (Colleen). Another participant who was very concerned about the seriousness of her
diagnosis was told she was HPV+ as an afterthought by her clinic, “they were, like, ‘oh and by the way
you have HPV sorry we did not call you, we forgot’.… I remember them botching the situation... they
forgot to call me, if I had not called them I don't think they ever would have told me... unless I would
have pursued getting whatever test redo and been, like, ‘hey what's going on’.... so I was really really
unimpressed with how the whole thing was handled. I was, like, you know what I am going somewhere
else” (Erica). Another participant who was mortified upon diagnosis, found out her status from a nurse
in an abrupt manner: “the nurse or whoever was working was very abrupt and she was, like, ‘you have
warts’ and I did not understand what was happening... so I then went and got tested for everything and
she said I had HPV... so that was when I was technically diagnosed the first time” (Ashley). Another
participant who was worried that HPV could lead to death stated: “I found out [that I had HPV] from my
Pap test from my annual gynecological visit that I hate... the worst day of the year every year... she just..
it was kind of casual when she called me and told me ‘oh yeah you tested positive for that and
everything else is good.’ I was, like, ‘whoa whoa lets back up to the tested positive for that’... it wasn't
the doctor who told me, it was a nurse in the office and she just kind of railroaded past it like it is not a
big deal, she acted like it was nothing” (Janelle).
Four participants recalled finding out they had HPV and their doctors or clinical staff assumed
they already knew because it was in their medical records. All of these participants experienced negative
emotions upon HPV diagnosis. One participant felt ashamed about her diagnosis, but did not feel
offended by this assumption stating: “Given my age [late 40’s], I think my doctor assumed I knew, so she
called me up and was, like, ‘your pap was abnormal so we have to do this LEEP procedure.’ I was
focusing on that and then she said and ‘you have HPV’” (Whitney). However, others recall being shocked
by their doctor or nurse’s bluntness. One participant who described herself as “broken” when
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diagnosed, recounts the negative exchange she had with her doctor: “He was, like, ‘well you do carry the
Human Papillomavirus (HPV)’ and I was, like, ‘what? I did not know that I had that’ and he was, like, ‘yea
you have had to have had it for a while’ …. I was, like, ‘I have been with the same person for 6 years …
no one told me this’…I wish my doctor told me … it feels, like, they are definitely keeping it a secret. Like,
the doctors are not telling us” (Kaylee). Another participant experienced a similar late diagnosis: “I did
not find out that HPV was the cause of my dysplasia until many years later when I was digging through
my medical records with my doctor after they told me my dysplasia was back... there is actually a 3 year
long story of that.. so the dysplasia at 20 which they did a LEEP for was definitely HPV but I did not know
that until years later which I was kind of pissed about …so I sat there with the nurse practitioner and my
medical records and we went through it and I was, like, ‘tell me what the fuck is going on here’…. so
they saw the old HPV results so there it was clear as day and piece of paper from when I was 20 years
old saying HPV positive… so I am 33 now… so 13 years ago around they thought it was not important to
tell you, you had HPV.. they knew it” (Riley). This particular participant felt so ill-informed by her earlier
clinicians about HPV that she felt extreme anxiety from her condition stating: “I was, like, I am going to
die of cancer… because I did not know it was a communicable virus that caused it I thought my body had
manifested cancer at 20 years old” (Riley).
Another who said she was “scared” upon diagnosis found out she had HPV only after asking
questions about her last abnormal Pap test, “No they CALLED me and said, ‘you have another abnormal
pap smear’ and .... I was worried about getting the biopsy again because the first one was painful…. so I
was, like, ‘is there any way we can do something else?’ And I was asking them all these questions and
the woman was like... she said very bluntly something, like, ‘how long have you known you've had this
disease?’ and I was just ‘what disease are you talking about’ and she told me and then I was at home
and I did a bunch of research that day” (Summer).
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Only three out of 23 participants felt supported by their doctors at diagnosis in such a way that
they felt less emotional upheaval after discussing their diagnosis with their doctor. One participant
reasoned that having confidence in her informative doctor possibly prevented her from having an
emotional response to the diagnosis stating: “I don't really remember having a strong emotional
response to it. I mean I was worried about it but I tended to have a good bit of faith in the medical
profession. It’s kind of, like, ok this is cool this guy knows what's going on and what to do next and he's
going to take care of it. It's not cancer yet so I think we are ok” (Leah).
Two of the 23 participants who were upset upon initial diagnosis had their worries assuaged by
the doctors. One of these participants stated that upon initial diagnosis: “I started crying. I was really
upset because I was not really educated and did not know what it meant and then he [doctor] kind of
calmed me down and explained. He gave me an education on it and I feel like that was pre-Googling
everything” (Leslie). Another stated: “I was, like, panicking and crying and the doctor was, like, ‘oh no it
is going to be ok’ …. She said it really is so common and a lot of people are affected by this and it is not
going to harm you” (Ava).
Some participants, however, could not be assuaged by their doctors’ attempts to emotionally
support them. One participant stated, “when I found out about it I kind of just felt like I was broken...
even though he told me that there are tons of women that have it and its nothing to be scared of. He
told me I am not going to die from it or anything. It still made me feel like I wasn't a complete woman.
Especially considering what he said [that]... the hysterectomy thing is next... it diminished my value...
that's what it felt like” (Kaylee).” Another stated, “at the time I was kind of freaking out.... I was, like, oh
my god I have an STD... that was an emotional crisis for me even though she told me it was very
common ... it is not gonna hurt me at all in my future?.. I asked” (Ava).
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2.7

LIMITATIONS
Past qualitative research on HPV has relied on non-diverse samples of primarily white, college-

education women (see: Kosenko et al. 2012, Nack 2008). Although I sought to reveal the stories of a
diverse sample based on ethnicity, race, and educational attainment level, my sample was more
homogeneous than initially intended. My sample included cis-gender and gender non-conforming
biological females from different racial and ethnic groups ranging in age. However, I was unable to
include participants of varying levels of educational attainment. This may have been a result of my
sampling method, however, I also believe it is due to the fact that women with lower socioeconomic
status and less education are less likely to have regular gynecological appointments and routine Pap
tests compared to their more educated peers (Behbakht et al. 2004; Katz and Hofer 1994). Without
regular visits to the gynecologist and routine Papanicolaou tests, women are much less likely to know
they are HPV positive. Therefore, individuals who saw my flyers may have thought they did not qualify
because they did not know their positive status.
Despite this limitation, my research adds knowledge to the field because of the rich detail my
participants provided during their interviews. Many past researchers used surveys to analyze
knowledge, awareness, and attitudes regarding HPV, but qualitative researchers have found that semistructured interviews allow participants to demonstrate meanings attached to their STI diagnosis and
personal experiences of dealing with this new diagnosis (see: Gerend and Magloire 2008; Lee and Craft
2002). My work differs from existing studies where researchers ask undiagnosed women how they
would feel if they were diagnosed with HPV (see: Waller et al. 2007a). My interviews of HPV+
participants, however, fostered detailed discussion of actual lived experiences related to HPV diagnosis,
HPV knowledge, emotional impact of diagnosis, and patient-provider communication.

34

2.8

DISCUSSION
Numerous studies highlight the correlation between health literacy and health behaviors.

Researchers have found that many cervical cancer prevention brochures are written at reading levels
too difficult for most consumers (Helitzer 2012). Women under 40 years old with below-basic health
literacy have a lower probability of having a Pap test than women in the same age group with proficient
health literacy (Hanchate 2008). Individuals with higher health literacy levels have been found to have a
greater understanding of cervical cancer and pap smears (Tiraki and Yilmaz 2017). They are also more
likely to participate in prevention measures, such as Pap smears (Tiraki and Yilmaz 2017 ).
Two decades ago, researchers found that individuals with HPV were dissatisfied with their
health care providers’ handling of their diagnoses because their providers did not offer emotional
support, provide written information on HPV, or refer them to a specialist (Clarke and Ebel 1996).
Common barriers to discussing HPV for surgeons, clinical oncologists, and nurse specialists alike included
lack of knowledge about the virus and not feeling well informed about HPV (Dodd et al. 2016).
Researchers have discovered that practitioners’ non-discussion of HPV is influenced by a general lack of
knowledge, a difficulty in keeping up-to-date on ever evolving HPV facts, and concern that information
on HPV from pharmaceutical companies is biased (McSherry et al. 2012). They also cite patient-provider
issues as barriers to this communication, including: concern that they will embarrass their patient and
themselves; lack of a clear opening to facilitate discussion of HPV; difficulty explaining HPV to patient in
terms they can understand; fear that their discussion of HPV would be viewed as judgmental;
uncertainty of necessity to discuss potential transient infection with patient; and lack of time and
discussion aids for consultations with patients (McSherry et al. 2012). Other communication barriers to
HPV discussion include patient lack of knowledge or interest in the STI, and fear that women would not
follow through with Pap tests once they knew more about HPV (McSherry et al. 2012). Many head and
neck practitioners (who diagnosis individuals with high-risk HPV types linked to oropharyngeal
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squamous cell carcinoma) say they worry about patients blaming themselves after diagnosis (Dodd et al.
2016). Therefore, the practitioners try to assure their patients that they could not have done anything to
prevent their diagnosis (Dodd et al. 2016).
Researchers have suggested that practitioners’ messages about HPV are inadequate because
there is a dearth of HPV knowledge among the general public; it is not often included in sexual
education curriculum and those who are aware of HPV overestimate their risk of cancer (Warren and
Ebel 2005). Effectively communicating about HPV without causing undue psychosocial stress requires
skill and sensitivity on the part of the provider (Harper 2004). In fact, breaking bad news is cited as one
of the most difficult aspects of being a medical service provider, yet doctors often lack adequate training
in this area (Sparks et al. 2007). Therefore, practitioners must stay informed of the most current
scientific data on HPV and be able to educate their patients on the subject in an empathetic manner
(Diaz 2013).
Many of my participants received their HPV diagnosis over the phone which supports the
findings of past research (see Harvey-Knowles and Kosenko 2012; McCree et al. 2010). Doctors,
however, are best able to offer emotional support and correctly answer patient questions when they
diagnosis face-to-face (Harvey-Knowles and Kosenko 2012). Unsurprisingly, this method of diagnosis
communication is most preferred among patients (Harvey-Knowles and Kosenko 2012). When receiving
a diagnosis over the phone, patients often have many unanswered questions about HPV and how it will
impact them (Harvey-Knowles and Kosenko 2012).
According to past research, at diagnosis, some women recall experiencing supportive healthcare
providers who gave information on HPV while providing reassurance (Bertram and Magnussen 2008). In
my study, however, few participants cited having an empathetic, supportive, and informative doctor
who diagnosed them. To minimize the psychological distress associated with a positive diagnosis,
doctors should discuss abnormal results with their patients in a clear, concise, supportive manner (Diaz
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2013). Doctors should also be mindful of the timing of their discussion and their patients’ health literacy
level (Diaz 2013).
Doctors should consider key messages that may minimize the negative consequences of HPV
diagnosis such as: normalizing HPV by focusing on how it is easily transmitted through sexual activity,
highlighting the high prevalence of HPV and perhaps even stating that it is as common as the flu, and
reassuring patients that they do not need to modify their behavior because they did not cause their
status (Dodd 2016). In my study, participants who were knowledgeable about the high prevalence of
HPV were less worried when diagnosed. Only 15 of my 23 participants were aware of how common it
was after diagnosis, however, and only 3 of those were informed of this fact when receiving their
diagnosis.
Post-diagnosis, many individuals are ill-informed about other important aspects of the disease.
Only 8 participants in my study were aware of HPV’s link to cervical cancer after their own diagnosis.
Over half of the participants who knew this information learned it from a source other than their doctor
(Gardasil commercial or online). This is problematic because, without being informed by a doctor if their
particular strain of HPV was linked to cancer, these participants could assume the worst and suffer from
unnecessary stress. I found that women were also rarely told about HPV’s tendencies to lay dormant in
the body and clear after a few years. Some of my participants found out about clearance a while after
being diagnosed with HPV (through their own research, from a new doctor) and felt relief at the
prospect that they would not have HPV for a lifetime. Those who knew about HPV dormancy were less
likely try to link their diagnosis to pat sexual experiences or partners. Doctors should, therefore, inform
their patients, at time of diagnosis, about HPV dormancy and clearance in order to mitigate any feelings
of blame on partners, self-blame, or pessimism. Very few participants were correctly informed about
HPV transmission. Only four individuals stated that HPV could be transmitted from skin-to-skin contact
and only one of these participants remembers that information coming from their doctor. It is a public
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health issue that post-diagnosis, individuals are still misinformed about how this STI is transmitted.
Without correct information on this topic, HPV positive individuals can do nothing to stop the spread of
the disease.
I found, in support of past research (see Bertram and Magnussen 2008; Kosenko et al. 2014;
Perrin et al. 2006; Sharpe et al. 2006), that many individuals with HPV are misinformed about HPV.
Based on my research, I recommend that healthcare practitioners strongly consider taking the time to
have a face-to-face conversation with their patient when providing a positive HPV diagnosis. This may
alleviate some patient confusion and any undue worry. Providers should also discuss with their patient
the high prevalence of HPV at time of diagnosis. According to my research, which supports the findings
of Bertram and Magnussen (2008), this discussion of prevalence is much appreciated by patients and
can ease their minds upon initial diagnosis. Based on my findings, I also recommend that doctors make
sure their patients are fully informed about key aspects of the disease: transmission, dormancy,
clearance, and how, specifically, it is linked to cancer.
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3
3.1

“She’s a Slut, She Has HPV”: HPV Stigma and Disclosure

ABSTRACT
Human Papillomavirus (HPV) is the most prevalent sexually transmitted infection in the United

States, however, many Americans negatively view the disease and those infected with it. This study uses
in-person, semi-structured interviews to examine feelings of stigma among individuals with HPV. It also
analyzes how these feelings and HPV knowledge impacted individuals’ motivations to disclose their
status to others. The study found that post-diagnosis many individuals were anxious and upset about
their positive status and felt judged by some individuals in their lives. Confronting and internalizing this
stigma, impacted how and why they disclosed and withheld their positive HPV status. These findings
suggest that the culture around HPV needs to change so that individuals with a positive status no longer
undergo undue stress and can openly educate others about the STI.

3.2

INTRODUCTION
Human Papillomavirus (HPV) is transmitted most commonly through sexual contact, such as

intimate skin-to-skin contact, and vaginal, anal, and oral sex (Moscicki 2005). It is the most prevalent
sexually transmitted infection in the U.S. (CDC 2017a). According to 2016 data, nearly 79 million
Americans are infected with HPV, with 14 million becoming newly infected annually (CDC 2017a).
Increased incidence of HPV has long been associated with greater number of sexual partners and “risky”
sexual behavior (e.g., multiple partners, unprotected sex). However, according to recent longitudinal
research, HPV detection, on average, occurs within 2.6 months of first intercourse (Collins et al. 2002). In
fact, Collins et al. suggest that “perhaps cervical human papillomavirus infection should now be
considered an inevitable consequence of sexual activity” (2002:98).
Despite the high prevalence and easy transmission of this STI, many Americans negatively view
the disease and those infected with it. Individuals with an STI often report disclosing their diagnosis
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because keeping it secret interferes with their relationships with others (Lee and Craft 2002). By
disclosing their condition, individuals with STIs can be reassured that they have not changed postdiagnosis (Lee and Craft 2002). According to Lee and Craft, “through telling, the respondents get
verification that they are still the same persons they were before genital herpes” (Lee and Craft 2002,
286).
Past research indicates that women feel more stigmatized and rejected socially when diagnosed
with an STI, compared to men (Smith et al. 2007). Past research indicates that women are more likely
than men to hide their STI diagnosis due to embarrassment (Smith et al. 2007). Additionally, women
with STIs report internalizing their stigma and believing the stereotypes are true for them (East et al.
2012). Women’s disproportionate stigmatization stems from historic blame of women as the vectors of
sexually transmitted infections (East et al. 2012; Nack 2008).

3.3
3.3.1

THEORY
Stigma

The symbolic interactionist approach, specifically Goffman’s theory on stigma is an appropriate
framework through which to investigate the experience of living with HPV. According to Goffman,
stigma is a less desirable attribute than one stereotypically assigned to persons of the same category
(Goffman 1963:3). Stigmas can be related to character flaws, which are personality traits that deviate
from those socially accepted or by physical deformities (Goffman 1963). Society views women who stray
from the societal norms of female chastity and purity as deviant, morally corrupt, irresponsible, unclean,
and promiscuous (East et al. 2012; Nack 2008). Therefore, they possess a character stigma (Nack 2008).
When an individual’s dissimilarity is not obvious upon first meeting, they have a “discreditable
stigma,” which can be hidden (Goffman 1963:42). They must determine what to tell or not tell and to
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whom and when (Goffman 1963). According to symbolic interactionists, individuals incorporate others’
evaluations of them when self-evaluating (Nack 2008:65). Therefore, they may choose not to disclose
their discreditable stigma, and instead, to hide it from others. Other discreditable persons, however,
may reveal their shameful attribute to a few key individuals and then rely on those individuals for
support (Goffman 1963). Alternatively, an individual can self-disclose and admit to having the stigma if
they no longer feel the need to conceal it (Goffman 1963).
Recent research on stigma also lends itself to this analysis. HPV stigma researchers that used the
HIV Stigma Scale found that feelings of uncleanliness and disgust with oneself, categorized as negative
self-image stigma, and fear of rejection, categorized as personalized stigma, were often felt by
individuals with HPV (Barnack-Tavlaris et al. 2016). Attribution theorists suggest that individuals with
illness that may be attributed to their behavior will face more judgement and stigma from others (Lebel
and Devins 2008; Weiner, Perry and Magnusson 1988). As noted above, individuals with HPV are often
seen as promiscuous and thus to blame for their sexually transmitted HPV (Nack 2008).

3.4

CURRENT STUDY
Research centered on individuals’ experiences of STI stigma is often related to genital herpes

(see: Lee and Craft 2002), or a multitude of STIs including HPV, genital herpes, and chlamydia (see East
et al. 2012, Nack 2000). Stigma related HPV research is often conducted outside of the United States
(see: McCaffery et al. 2004, McCaffery et al. 2006, Waller et al. 2007a) and is survey based (see:
McCaffery et al. 2004, Waller et al. 2007a). Through my research, I sought to discover how an HPV +
status, a character stigma, influenced my participants’ feelings about themselves, and why they decided
whether or not to disclose their status to family and friends.
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3.5

METHODS
Due to the fact that individuals with STIs qualify as a hard-to-reach population and recruitment

can be difficult (Dixon-Woods et al. 2001; Nack 2008), I employed purposive, facility-based sampling and
snowball sampling. I utilized key locations to find study participants (Magnani et al. 2005), such the
health clinic at a large public university in the Southeastern United States and multiple privatelyoperated gynecological clinics around a large metropolitan area in the Southeastern United States.
Commonly cited barriers to STI screenings include cost, privacy, language barriers, and perceived
discrimination at the clinical site (Tilson et al. 2004). Therefore, I chose to include clinics that offer free
or low-cost STI screening services to English and non-English speakers and that abide by antidiscrimination laws specific to patient admission and treatment. I also posted flyers around two major
universities, high-traffic pedestrian areas, and throughout diverse neighborhoods. Additionally, I gained
entry into online support groups for individuals with HPV9 to recruit group members for my study.
I recruited my participants via advertisements (flyers) displayed and distributed at the recruitment
facilities. This discreet recruitment method is commonly used among STI researchers (see: Kosenko et al.
2012; East et al. 2012) so that interested parties can contact the researcher anonymously with any
questions. Multiple versions of the flyer were distributed with various photos of young girls and women
from different racial and ethnic groups on them in order to appeal to a diverse group of potential
participants. Each flyer contained tear-off tabs so that interested parties could easily obtain my contact
information. Additionally, each flyer included a Quick Response code. Quick Response codes are an
increasingly popular advertisement tool that can be scanned and read by smartphones (Shin, Jung, and
Chang 2012). The flyers contained a unique Quick Response code that linked smartphone users to my
online eligibility form. This eligibility form required users to enter their age and HPV status and then, if
eligible and interested in participating, their contact information was automatically sent to me.
9

http://www.dailystrength.org/c/HPV/support-group; http://hpvsupport.com/phpBB3/;
http://www.mdjunction.com/hpv; http://hpv.supportgroups.com/; http://www.hpvhope.com/support.html;
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3.5.1

Sample Demographics

I gave all of my participants pseudonyms to protect their identity. My participants included 23
women of various ages10. Six were in their 20s, eleven in their 30s, three in their 40s, two in their 50s,
and one over 60 years old. Sixteen of the 23 participants grew up in a two-parent family; three had a
single parent; three had divorced parents and stepparents in the home; and one had divorced parents
that never remarried. Twelve of my participants grew up in the Southeastern United States. Six of my
participants grew up in the Northeast; three grew up in the Midwest; and two grew up outside of the
United States. Fifteen of the participants resided in the Southeastern U.S. at the time of their interviews
with three living in the Northeast; one in the Southwest; two in the West; and two outside of the United
States. My sample was a highly educated group, with 10 of my participants having obtained a graduate
degree, four in graduate school at the time of interview, six obtaining a terminal Bachelor’s degree, one
currently in undergraduate school at the time of interview, one having had some college education, and
one having a GED as highest level of education. Regarding occupation, eight worked in health and
medicine, four in education, three in law, three in the arts, one in business administration, one in
marketing, one in plumbing/engineering, and two as current students. The majority of my participants
were white (n=17, 73.9%), five (21.7%) were black, and one (4.35%) was multiracial. Ten of my
participants were single at the time of interview, 8 were in a committed relationship, and 5 were legally
married. In terms of gender identity, 22 of my participants identified as women and one identified as
gender queer. In terms of sexual orientation, 18 classified themselves as heterosexual, one as lesbian,
and four as bisexual.

10

My sample originally included 25 individuals, but after the interview, I determined that two no longer qualified
to be included, due to their type of HPV. Both of those original participants had HPV that manifested as skin warts
on the hands and feet – a condition that is not considered a sexually transmitted infection and is not related to
reproductive issues or cancers.
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3.5.2

Interview Method

Although many past researchers have used surveys to analyze knowledge, awareness,
and attitudes regarding HPV and the vaccine, other researchers find that semi-structured interviews
allow participants to explain their personal experiences of dealing with STI diagnosis and what this
diagnosis meant to them (see: Gerend and Magloire 2008; Lee and Craft 2002). Interviews of HPV+
participants, compared to survey research, are more likely to foster discussion of actual lived
experiences related to living with HPV and disclosure to others, and stigma.
As a feminist interviewer, I was cognizant of my role as a researcher and my potential
source of authority during the interview process (Hesse-Biber 2007). In order to diminish the
hierarchical relationship between researcher and participants, after each interview, I shared relevant
aspects of my own biography (Hesse-Biber 2007) and experience with HPV. I strove to be reflexive and
to consider how my biography, values, and attitudes influenced the research process (DeVault and Gross
2012; Hesse-Biber 2007). As a woman with HPV, throughout the interview and analysis stages, I
reflected on how my attitudes regarding the disease impacted my choice of interview questions and my
interpretation of participants’ responses (DeVault and Gross 2012). For example, I was motivated to ask
about disclosure to friends and family because of my own decision-making about disclosure. My
personal experience also helped me understand the participants’ willingness or hesitation to tell others
about their status.
Interview topics included: how participants felt about themselves post-diagnosis, to whom they
disclosed their status, and reasons for their disclosure and non-disclosure of status.
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3.5.3

Analysis
I conducted, recorded, and transcribed all of the interviews. I imported all transcribed materials

into NVivo and analyzed them using a grounded theory approach. I chose this analytic method because
it is well suited for understanding social processes not yet commonly researched (Milliken 2010). And, as
noted above, there have been very few qualitative studies on the lived experiences of individuals with
HPV. From my transcription and pre-analysis coding, I identified a few themes that I wanted to further
investigate related to consequences of HPV: “stigma,” “disclosure,” and “initial impact of diagnosis”. I
analyzed the transcripts using the triadic coding scheme of open, axial, and selective coding (LaRossa
2005). During open coding, I identified major themes related to stigma, emotional response to diagnosis,
and disclosure to friends and family, and deciphered what each concept represented (Lofland et al.
2005; LaRossa 2005). In the context of their diagnosis, each participant mentioned how they felt about
their diagnosis and who they told about it. I then reviewed the concepts for similarities and variations,
assigned them to categories, and identified the most salient categories (Corbin and Strauss 1990). I
analyzed consequences of HPV to determine how participants felt when first diagnosed, whether or not
participants felt stigma due to their status, to whom and when they disclosed their status , and why they
decided not to disclose their status to some individuals, if applicable.
In the axial coding stage, I analyzed the categories to determine how and why they differed
among the participants, by focusing on the context, strategies, and consequences associated with each
category (Corbin and Strauss 1990; LaRossa 2005). I analyzed relationships between participants’
experience with the diagnosis, stigma, and disclosure. Finally, I moved on to the selective coding stage
of my analysis, where I decided which categories were most representative of the central argument of
my analysis (Corbin and Strauss 1990; LaRossa 2005). I found the relationship between stigma and
disclosure to friends and family to be most informative in this study.
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3.6

FINDINGS

3.6.1
3.6.1.1

Stigma
Participants Who Felt Little to No Stigma

Nine participants felt little to no stigma associated with their HPV status. One stated, “since
everybody has it, I feel like it is a bacteria that lives in everyone. I don't think it has any stigma the way
HIV has stigma” (Andrea). A few individuals mentioned not feeling stigma because of the types of people
they acquaint themselves with, “I think it depends on the type of people that you date and I tend to
date people that are educated so I could see where someone who was dating uneducated men or
women, that they could feel more stigmatized” (Leslie). Another similarly articulated, “no [I do not feel
stigma] but I guess on top of that, the part of society I interact with aligns very closely with what I
believe and how I live my life” (Erica). Those that were aware of the high prevalence of HPV and/or
associated with individuals who were more knowledgeable about HPV felt less HPV stigma.
Three of these participants recognized the stigma attached to HPV even when they did not
experience it themselves. One individual recalled a friends’ reaction to her own HPV diagnosis, “you
would have thought she was the whore of Babylon. She thought she was a horrible person, ‘how could
this happen, who could have given this to me? I have not had that much sex’” (McKenzie). Another
participant explained how others with HPV often feel by saying, “I think that most people end up
thinking they are punished or they are dirty or because that boy or that person or that bad decision... I
think that everybody has that because sex has a terrible stigma attached to it” (Riley). This individual
recalled how societal pressures on women translated into women with HPV feeling at blame, “I feel like
since you can't test men, then it becomes the women's problem and the dirty slutty women, we are the
ones carrying it around. It has that feel to it. And the women that I have known that are diagnosed have
been devastated” (Riley). Another recalled men friends saying “she had HPV, she's gross” but equates
this stigmatizing behavior to people being ignorant about HPV, “they are uneducated about it… I just tell
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them they are wrong and explain. It's just miseducation” (Leslie). These participants, even if
experiencing no stigma personally, understood how many individuals with HPV could feel judged by
others and internalize that judgement.

3.6.1.2

Participants Who Felt Stigma
Fourteen participants explicitly mentioned feeling stigma due to their HPV status. Ten of these

participants felt judged by others. One did not tell her mother about her HPV “because there is a level of
shame that comes with stuff like this that is not acceptable” (Ashley). Another worried what her family
would think, saying: “I believe that they would [be judgmental]. My family on my mother's side …oh yes,
they are very… a different breed. They would probably blame it on me…. ‘That's what you get’ type of
thing” (Kaylee). Another told a friend for support and was shamed for it, “I told a friend of mine about
what happened at the clinic [my diagnosis] and she told everybody that I had a venereal disease”
(Ashley). One participant vocalized what she assumes others think about HPV, “most people who
haven't done the research themselves, despite what I would have to say, would be very quick to just
hear STD, and judgment, and all the stigma that comes along with that” (Amber). One individual worried
about potential stigma from a friend, “I had a close friend at work and we were on a departmental team
together and one of the girls was in and out a lot and she was having reproductive problems. So, my
friend was like ‘she's a slut.... She has HPV’” (Summer). Another felt her status reflected poorly on her in
the eyes of others, “if you say that you have HPV that is like saying I have had unprotected sex”
(Whitney). She worried about being judged for her status and sexual behavior.
Two of the participants who felt judged by others believed this was related to the form of cancer
they had from HPV. One felt judged by the diagnosing doctor, recalling “it comes back [as] HPV and my
doctor down here tells me I need to change my lifestyle…. He is supposed to be learned about these
things and be accepting. Whether I was partaking in anal intercourse or not was not his call” (Theresa).

47

Another explained, “I was first diagnosed [with anal cancer] and I had to tell my boss and all of a sudden
it was just like they did not want to hear about it. I think people are just very put off by cancer that is
caused by something that could be sexually related.... Of course, nobody wants to say anal and when
they do it is in a negative context” (Katherine). Both of these participants had HPV which led to anal
cancer. They believed they were being judged for their status and cancer because of how they are
acquired.
Seven of these fourteen participants internalized the stigma and judged themselves. One
individual explained, “she [mom] was kind of pissed at me for getting HPV and having to have this
colposcopy11.... I remember not wanting to deal with that and maybe feeling a little ashamed and shitty
like she was making me feel shitty” (Phoebe). Another stated, “I was really fascinated with how I was
identifying with my body…the physical part of my body that nobody could see but me...and how much I
internalized that. I felt dirty and I felt gross. I felt ugly and I did not feel sexually viable, but nobody knew
that but me. Thinking about it…it grosses me out. It takes me back to that feeling of shame…really
shameful. I did not do anything that shameful; it just kind of happened. But it made me feel shameful. I
felt this internalized sense of dirty” (Emily). Another said, “there was a little bit of like...the dirty
feeling.... I have a sexual.... No one wants to say that about themselves….[It] left a sour feeling in my
stomach” (Summer). Another voiced similar feelings, stating, “it is just embarrassing and you know you
feel dirty and feel that there is something wrong with me. After that [diagnosis], I feel ashamed”
(Whitney). She continued, “I am kind of upset with myself. I know who exactly I got it from and I should
have been more assertive about using.... You know, I judge myself. I should have been more assertive
about using condoms…. I just feel like at my age, I should have known better” (Whitney). Another felt
shame at her diagnosis, “after the diagnosis, I was like, that sucks. I really had pride about the fact that I

11

A colposcopy is often recommended after an abnormal pap result. During this procedure, a health care provider
examines the cervix through a colposcope and, if need be, performs a biopsy of the cervix for laboratory testing
(Johns Hopkins n.d.).
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had never been diagnosed with an STD…. After this diagnosis, I thought, you can't say that anymore, you
are like everybody else and you now have HPV which is considered an STI” (Colleen). A few of these
participants blamed themselves for their diagnosis: “I guess you paid for that piece of ass” (Theresa),
and “I think that I got genital warts, not because of the strain, but because I was treating my body very
unhealthy” (Emily). All of these participants viewed themselves negatively at some point since their
diagnosis because of their status, sexual behavior, or how others judged them.
Three of these participants felt stigmatized when first diagnosed, but felt less so over time. One
participant demonstrated that she was upset at diagnosis, but no longer internalizes that stigma,
“growing up things I heard like STDs have a stigma … this connotation that she must sleep around or
that he sleeps around or that I don't use protection or that I am not responsible.... I am dirty…damaged
goods…. It was a rough moment… in that first day or two that I learned I had it.... That is why I was so
upset because STDs have a very.... It is like…oh, I am that statistic now. I am part of that group.... So it
was hard, but now it is no big deal to me now. I know more about it. I don't think that way anymore”
(Ava). One participant explained, “[I felt stigma] just in the very beginning when my friend told people I
had a venereal disease” (Ashley). Another stated, “it did feel like a little bit of a stigma. I had done a
bunch of reading and it was like...it is ridiculously common and very easily transmitted and people often
don't know if they have it. But it still, it did feel a little bit like...you know I had this disease now.... I don't
think it was a very lasting kind of impact but I definitely was aware of it” (Jessie). These participants’
sense of self-blame and internalized stigma dissipated over time when they gained more knowledge
about HPV.
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3.6.2

Disclosure

Twenty-two participants mentioned disclosing their HPV + status to at least one person in their life.
These participants disclosed to friends, family members, sexual partners (see Article 3), and/or other
people with HPV. Two of these individuals revealed their status to only one person in their life.
Disclosure was often related to a feeling of stigma related to HPV, or a lack thereof.

3.6.2.1

Stigma and Disclosure

Twelve participants who felt stigma from their HPV status decided to disclose to individuals close to
them for a variety of reasons. Two only told their sexual partner; one disclosed to only one person, a
close friend; nine participants mentioned their HPV status to friends and/or family members. Some
participants disclosed because it merely came up in conversation with their family or friends. Others
tended to offer this information when giving advice to others. One explained, “whenever any of my
friends mention their gynecologist doing any overt testing…I felt like they were treating me really
aggressively and did a lot of stuff that didn't need to happen…. So recently I feel like I have been a lot
more open about it to my friends” (Summer). Many of the participants disclosed to friends who had
previously been diagnosed with HPV or who were more knowledgeable about the STI. One individual
stated, “[I told] one of the girls I worked with because she had gone through it. I just asked her about it
one day. She is my older friend. I just asked if she had ever had the same issue and she had. She was like
yeah it is super uncomfortable but lots of women have had to deal with it [HPV and colposcopy]. She
was the only person I really talked to about it because it was just this thing I had to do” (Ashley). One
recalled that she mentioned having it after her friend revealed her own status, however, she refrained
from disclosing all aspects of her diagnosis, “the only thing I don't talk about is the genital warts”
(Emily). Others told friends who may have been more knowledgeable about HPV. One recalled, “I talked
to my roommate who is a nurse because I had told her before I got diagnosed. I was like there is this

50

thing that I got - what do I do?” (Ava). These participants decided to tell their status to others in order to
gain knowledge about their own diagnosis or to inform others about HPV.
The participant who disclosed to only one friend recalled telling her right after diagnosis, “I'm
like, ‘guess what just happened? I got a call about my pap smear.’ I called her like, ‘do you believe this?’ I
made a special call with that in mind” (Janelle). Although this friend was supportive, she knew very little
about HPV; “she did not know anything more than I did so she wanted to know what I found out about
HPV” (Janelle). Most participants who disclosed to their friends felt supported. Friends often pointed out
that HPV was “really common and they were sure I would be fine,” (Jessie) and, “it's no big deal, this
happens all the time” (Summer).

3.6.2.2

Stigma and Non- Disclosure
One individual made the conscious decision to tell no one. This participant stated that her

motivation for non-disclosure was related to the judgment she would receive due to people’s lack of
HPV knowledge: “I just feel like it would be awkward you know telling someone that you have an STI.
Especially the people that I talk to that are not really educated about it - I don't want an ignorant
response” (Kendra). This individual also felt that friends would pass judgment, therefore she did not
disclose her status to them: “they are virgins so our conversations about sex are very limited. It would
be awkward to tell them because they just want to dis it” (Kendra). This participants assumed that
individuals in her life lacked the necessary sexual experience and HPV knowledge to understand her
status.
Fourteen of the participants who felt stigma at some point in their life related to their HPV
status refrained from disclosing their status to some individuals close to them. Eight did not tell their
status to their most recent sexual partners, and one did not mention it to any of their sexual partners.
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(Disclosure to sexual partners is the topic of another article.) Six participants chose to not disclose their
status to others close to them.
A few participants withheld their status from specific individuals in their life while telling others.
One withheld this information from her mother’s side of the family, also due to fear of stigma, stating,
“it’s not like they aren't going to be judgmental or anything. I just wanted to keep it to myself” (Kaylee).
However, this participant also did not tell the rest of her family about her status because she felt
disclosure was not important due to HPV’s prevalence: “I haven't mentioned it. I don't know.... It seems
like it has been normalized. It is not so much of a big deal to me for me to tell anyone else because there
are lots of people that are going through it too” (Kaylee). Another individual voiced similar motivations
for non-disclosure to most friends and family stating, “I guess if it had been something I was more
worried about especially with my medical health, I would have talked to my parents about it” (Jessie).
These participants felt they had nothing to gain from disclosure because it was not a cause for concern.
Another withheld her status from friends, not due to stigma, but due to there being no benefit in
disclosing, “because it is none of their [friends’] business. They can't help me. There is absolutely
nothing they can do to help me” (Janelle). She felt that telling others about her status would not help
her handle the aftermath of her diagnosis.

3.6.2.3

No Stigma and Disclosure

Nine participants who felt little to no stigma related to their HPV status disclosed their status. Many
of these participants discussed HPV with friends who had been previously diagnosed or had undergone
HPV-related procedures. One felt relieved after discussing HPV with friends who had it, saying, “that
they essentially had the same diagnosis that I did and like a year later they didn't have it anymore and it
didn't affect their sex life or their life in general” (Leslie). This participant reached out to friends she
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knew who had HPV to ask about their experiences, “I was having to get those procedures done. I was
asking if anyone had it before and one of them had and we talked about it” (Leslie). Another recalled,
“One of my good friends was diagnosed with the genital warts type. So, I talked to her about it” (Carla).
These participants felt supported by their friends and gained valuable knowledge about HPV, both of
which may have led to less feelings of stigmatization.
Three participants were very open about having HPV. One noted how she tells most people, but
educates them while doing so, “I am very open with my friends... if I am around a conversation where
people are talking about STDs... I will disclose … to educate people” (McKenzie). Another mentioned, “I
would tell anybody. If it was a topic of conversation and relevant, I would happily speak about it” (Riley).
These participants were very candid about their status and disclosed to most people in their lives.
Others felt open about their status, yet did not tell everyone in their life. One participant
revealed her status to her partner and family, yet did not reveal it to most friends. This was not a
purposeful non-disclosure, as she states, “we are a fairly open group so I don't think that it was
something that I tried to hide. If it had come up in conversation I don't think I would have been worried
to disclose.... Just to the best of my recollection I don't think it came up” (Leah). Many participants said
that they would disclose if it came up in conversation with friends or family. One individual, who was
diagnosed a year prior to the interview, mentioned how the passage of time since diagnosis has made
disclosure easier: “I think the farther away it has gotten from the diagnosis, it is not something I feel like
I need to hide if it ever came up in a conversation” (Erica). Although this participant felt little to no HPV
stigma and openly disclosed to friends, she is now more candid about her status with others in her life if
it is relevant to the conversation.
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Two participants disclosed their status to a few family members and friends only in the context
of HPV-related treatment and lab results (LEEP12, abnormal pap smear, colposcopy) while rarely drawing
a connection to HPV. One participant decided to not disclose her HPV to most of the people in her life,
but discussed treatments with friends and family members recalling, “when I was going to be out for a
few days [for LEEP] and that was it…I think I probably glossed over the fact that you need LEEP if you
have HPV - the connection” (Candace). She did, however, draw the connection, and thus disclosed her
status, to close friends, “I think the only time I disclosed was when I was about to have the LEEP and
people wanted to know why…I think I said it was because of HPV” (Candace). Another participant
disclosed her HPV to her sexual partner but only discussed treatments with family while withholding her
HPV status from them, “I talked to my parents and sister about the treatments. No one has ever
mentioned HPV. I haven't mentioned it to them. I don't want to have that conversation with my
mother” (Andrea). She assumed her parents and sister did not understand that the treatments were
associated with HPV because they did not draw the connection on their own and discuss it with her.

3.7

LIMITATIONS
Past qualitative research on HPV has relied on non-diverse samples of primarily white, college-

educated women (see: Kosenko et al. 2012, Nack 2008). Although I sought to reveal the stories of a
diverse sample in terms of ethnicity, race, and educational attainment level, my sample was more
homogeneous than initially intended. My sample included cis-gender and gender non-conforming
women from different racial and ethnic groups ranging in age. However, I was unable to include
participants of varying levels of educational attainment. This may have been a result of my sampling
method. However, I also believe it is due to the fact that women with lower socioeconomic status and
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With LEEP, an electric current heated wire loop removes abnormal cells and tissues in the cervix and vagina. The
tissue is then sent to a lab for testing. LEEP is often performed in order to detect cancer of the cervix or vagina
(Johns Hopkins n.d.).
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less education are less likely to have regular gynecological appointments and routine Pap tests,
compared to their more educated peers (Behbakht et al. 2004; Katz and Hofer 1994). Without regular
visits to the gynecologist and routine Pap tests, women are much less likely to know they are HPV
positive. Therefore, individuals who saw my flyers may have thought they did not qualify because they
did not know their positive status.
Despite this limitation, my research adds knowledge to the field because of the rich detail my
participants provided during their interviews. Many past researchers used surveys to analyze
knowledge, awareness, and attitudes regarding HPV, but qualitative researchers have found that semistructured interviews allow participants to explain personal experiences related to this diagnosis (see:
Gerend and Magloire 2008; Lee and Craft 2002). My work differs from existing studies where
researchers ask undiagnosed women how they would feel if they were diagnosed with HPV (see, e.g.,
Waller et al. 2007a). My interviews of HPV+ participants fostered detailed discussion of actual lived
experiences related to HPV diagnosis, disclosure, and stigma.

3.8

DISCUSSION
According to past research, some HPV + individuals do not feel stigma associated with their

diagnosis and instead view it as an inevitable consequence of being sexually active (McCaffery 2006).
While nine of the participants in this study felt little to no stigma associated with their status, fourteen
did feel stigma associated with having HPV.
Individuals’ embarrassment and shame surrounding diagnosis often stems from the
connotations of promiscuity associated with STIs (McCaffery et al. 2006). My findings support this past
research, with many of my participants voicing worry about being judged for having a sexually
transmitted infection. They thought others would associate their diagnosis with having unprotected sex
and sleeping around. Individuals with STIs may face increased prejudice because they potentially caused
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their own stigma (Breitkopf 2004; Nack 2008). Attribution theorists posit that those who are seen as
contributors to their own illness are often more harshly judged by others (Lebel and Devins 2008;
Weiner, Perry and Magnusson 1988). It is socially acceptable to blame individuals for contracting
infectious illnesses (Breitkopf 2004; Nack 2008). Research indicates that blame is more often attributed
to women with cervical cancer than to individuals with cancers unrelated to lifestyle choices, such as
leukemia, breast, or bowel cancer (Marlow et al. 2010, 1802). While many of my participants worried
about judgment from friends or family due to their status being linked to sexual behaviors, only one felt
this judgment from their diagnosing doctor. This participant felt that her doctor was blaming her for
having HPV because of assumed sexual behavior.
Women with STIs often internalize this stigma (East et al. 2012). In fact, the most commonly
reported type of stigma among individuals with HPV is negative self-image stigma (Barnack-Tavlaris et al.
2016). Women with HPV often refer to themselves as “unclean, “dirty”, “cheap”, “gross” (East et al.
2012, 17; McCaffery et al. 2006; Nack 2008, 66). Some of my participants echoed these sentiments and
mentioned feeling “ashamed”, “dirty”, “gross”, “ugly”, “damaged”, and “no longer sexually viable”.
Women sometimes stated that their diagnosis signified them paying for past behaviors (Daley et al.
2008). A few of my participants recalled feeling disappointed in themselves for not using condoms or
having safer sex. Others recalled feeling that their diagnosis was retribution for having sex with a
particular person or for treating their body poorly. Researchers have found this type of self-blame is
more common among individuals with STIs, such as HIV, compared to unavoidable illnesses, such as
some forms of cancer (Fife and Wright 2000).
When an individual’s “differentness is not immediately apparent, and is not known
beforehand,” she has a discreditable stigma, according to Goffman (1963, p. 42). My participants’ HPV
status was not known to others unless disclosed, making them discreditable. Discreditable individuals
engage in strategies of stigma management to control the information that others know about their
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discreditable attribute (Goffman 1963). Many individuals with HPV feel personalized stigma, where they
worry that others will not understand their diagnosis and reject them (Barnack-Tavlaris et al. 2016).
According to previous research, women with HPV feel anxiety about disclosing their status to family and
friends (East et al. 2012; Kosenko et al. 2012). Women with HPV often chose not to disclose their stigma
to others because they fear rejection from their friends, family, and sexual partners (Barnack-Tavlaris et
al. 2016; Nack 2008:91). Therefore, some individuals do not disclose their positive status in order to
avoid making a stressful situation more anxiety provoking (McCaffery et al. 2006). Over half of my
participants withheld this information from many individuals close to them due to fear of rejection and
judgment. One individual had not disclosed to anyone for the same reasons.
Individuals with a discreditable stigma may choose, however, to disclose their
discreditable attribute to others as a form of “stigma management” (Breitkopf 2004; Goffman
1963:100). Many women with HPV eventually disclose their stigma because they feel increasing guilt
about concealing it from friends and family (Nack 2008:91). Selective disclosure, another strategy for
managing stigma, is when an individual conceals their stigma to most and discloses it to a few people,
usually their intimates, family members, and doctors (Goffman, 1963). The majority of my participants
decided to disclose their status to at least one person in their life, their sexual partner(s), close friend(s),
or family member(s), but very few disclosed to everyone.
As a form of stigma management, individuals may pose as having a similar, yet less stigmatizing
condition in order to avoid judgement (Goffman 1963). Past research demonstrates that some
individuals chose to disclose their abnormal pap smear results rather than their HPV status (McCaffery
et al. 2006). A few of my participants mentioned their abnormal results or their HPV-related procedures
rather than disclosing their status as a way of avoiding full disclosure. By mentioning their lab results,
LEEP, or colposcopy these individuals made their friends and family aware that they were undergoing
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some type of cervical condition, but they did not disclose that this was related to a sexually transmitted
infection.
According to Goffman, close relationships cause a discreditable person to disclose their secret or
feel guilty for not doing so (1963). Many women disclose in order to gain the support of loved ones (Lee
and Craft 2002). All but one of my participants disclosed to close friends, family, or partners who were
supportive. One individual faced a single judgmental friend, but later found support in others. Seven
participants disclosed to friends who had previously been diagnosed or who had undergone an HPVrelated procedure. These participants found support and reassurance by disclosing their status. In-depth
HPV research reveals that after diagnosis, women face the harsh reality that many of their close friends
and family now see them as diseased (Nack 2008). Fortunately, this was not the case for my 22
participants who felt loved and supported once disclosing their status to select friends and/or family.
Another stigma management strategy for those with discreditable stigmas is self- disclosure
(Goffman, 1963, p. 100). An individual can self-disclose by openly admitting to having the stigma
(Goffman, 1963, p. 101). Many of my participants disclosed their status although they felt no stigma
associated with it. Many recalled that they disclosed because it merely came up in conversation. Others
told their HPV experience to individuals who had since been diagnosed as a way of offering advice and
support. Seven participants stated that their disclosure to others was a means for them to help
educated people about HPV. Goffman asserted that if an individual “accepts himself and respects
himself he will feel no need to conceal his failing” (Goffman, 1963, p. 101), three of my participants had
reached this point of self-acceptance and shared their HPV experience with most everyone in their lives.
Individuals with HPV often feel embarrassed about their diagnosis (Daley et al. 2008; Nack
2008). This embarrassment can lead to self-blame and non-disclosure of status. Although thirteen of my
participants felt HPV stigma at some point since diagnosis, almost all of them (12 of 13) told someone in
their life about their status. This disclosure is often beneficial to those with HPV. It can be cathartic and

58

allow them to seek sympathy and acceptance from close friends and family members (Nack 2008: 98).
My participants gained support and knowledge from their disclosure. Both of which were valuable
resources while trying to navigate what being HPV positive meant to them.
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4
4.1

“They Probably Already Had It Anyway”: Status Disclosure and Sexual Behavior

ABSTRACT
Human Papillomavirus (HPV) is the most prevalent sexually transmitted infection in the United

States, however, many Americans do not use preventive methods to protect themselves and others
from transmission. This study uses in-person, semi-structured interviews to examine status disclosure
and sexual behavior among those with HPV. It also analyzes how HPV transmission knowledge impacts
motivations and intentions to participate in prevention behaviors. The study found that post-diagnosis
many individuals were ill-informed about HPV transmission and how HPV impacts men. This study also
found that few individuals with HPV disclosed their status to all at-risk sex partners or used barrier
methods consistently during sex. These findings suggest that more work is needed to facilitate effective
HPV education which includes status disclosure and use of all barrier methods.

4.2

INTRODUCTION
Human Papillomavirus (HPV) is the most prevalent sexually transmitted infection in the U.S.

(CDC 2017a). Nearly 79 million Americans are infected with HPV, with 14 million becoming newly
infected annually (CDC 2017a). Over 40 types of HPV are transmitted through vaginal, anal, and oral sex,
or intimate skin-to-skin contact (CDC 2013; Moscicki 2005). Men are not currently tested for HPV and
screening tests are not available for HPV-related cancers or genital warts in men (CDC 2017b). The vast
majority of women diagnosed with HPV have strains that present low-risk for cancer (CDC 2013). At
least two of these low-risk strains are associated with genital warts, which are also transmitted through
sexual contact, highly infectious, and very common (WHO 2016).
HPV is the primary cause of cervical cancer in the U.S., with over 90% of cases caused by HPV
(CDC 2017c; Nan 2012). There are over 100 subtypes of HPV; however, only a few are associated with
cervical cancer (CDC 2013; Polzer and Knabe 2012). These high-risk types of HPV are also associated with
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other cancers. Anal cancer is strongly associated with high-risk HPV, although its occurrence is rare
(ASHA 2018). Over 80% of anal cancers in the United States are caused by high-risk HPV (CDC 2017c).
Men and women, especially those with a history of severe cervical dysplasia, can be affected by HPVrelated anal cancer (ASHA 2018). Head and neck cancers are also rare, but 70% of cases are associated
with high-risk HPV transmitted through oral sex (CDC 2017c; ASHA 2018). Penile cancer is extremely
rare, but has been linked to high-risk HPV in over 60% of cases (CDC 2017c; ASHA 2018). HPV is also
associated the rare vaginal and vulvar cancers, making up over 70% of those cases (CDC 2017c; ASHA
2018).

4.2.1

HPV Knowledge

Many Americans are unaware of HPV’s prevalence and risk of transmission (Blake et al. 2015;
Gerend and Magloire 2008; Sandfort and Pleasant 2009; Ratanasiripog et al. 2013). This knowledge
varies based on level of health literacy, education, age, and race (Blake et al. 2015; Kutner 2006).
However, even college educated individuals who are aware of HPV’s link to cervical cancer, tend to be
less knowledgeable about its prevalence and often do not perceive themselves at risk (Gerend and
Magloire 2008; Sandfort and Pleasant 2009; Ratanasiripong et al. 2013; Blake et al. 2015). These
individuals are also often unaware of HPV-related health threats to men and the risk of developing
genital or cervical warts (Sandfort and Pleasant 2009).
Prior to HPV+ diagnosis, many women report little concern about their health at the time of
their first abnormal Pap (Sharpe et al. 2006). Even women recently diagnosed with HPV lack information
about the infection (Perrin et al. 2006; Sharpe et al. 2006). They are confused about the symptoms,
treatment options, and recommended lifestyle changes (Perrin et al. 2006). Research indicates that
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women with HPV often lack knowledge about the sexual transmission and high prevalence of HPV
(Sharpe et al. 2006).
The HPV vaccine protects against persistent infection of HPV subtypes associated with most
cancers and genital and cervical warts (Rothman 2009; Brelsford 2011). In June of 2006 the HPV vaccine
was approved and recommended for girls aged 11-26 (allowing 9 and 10-year-old girls to be eligible for
the vaccine) (Braun and Phoun 2010; CDC 2011; Connell and Hunt 2010; Shefer et al. 2008; Wailoo et al.
2010). Although young girls (11 and 12-year-olds) are the targeted demographic for vaccination,
routinely the vaccination requires surrogate decision making, whereby parents decide if their child gets
vaccinated (Chapman 2010; Connell and Hunt 2010). Research demonstrates that parents of girls often
intend to vaccinate them against HPV before the age of 13 (Constantine and Jerman 2007). Vaccine
uptake among male adolescents is lower than females because most parents report a lack of awareness
of the health consequences for men and the possibility of administering the vaccine to boys (Reiter et al.
2011; Voss and Wofford 2016). In general, parents of girls and boys view the vaccine as safe and
effective in preventing cancer (Alexander et al. 2012; Brewer and Fazekas 2007; Rosenthal et al. 2008).
HPV vaccination intention is lower among older adolescents and college age women, compared
to younger girls. The most commonly cited barriers to vaccine intent among college age women were:
vaccine safety concerns, side effects, insurance issues, cost, and low perceived risk (Patel et al. 2012).
Past research demonstrates that younger (18 to 21-year-olds), white, insured women were more likely
to receive a doctor’s recommendation for the vaccine compared to older (22 to 26-year-olds),
uninsured, minority women (Gerend et al. 2015). Not surprisingly, the same demographic group is more
likely to receive the HPV vaccine: white, insured, 18 to 20-year-old women (Laz et al. 2013). The most
commonly cited barriers to vaccine intent and uptake among 18 to 26-year-old women were: vaccine
safety concerns, side effects, insurance issues, cost, low perceived risk, and the belief they were too old
to receive the vaccine (Laz et al. 2013; Patel et al. 2012). According to the CDC, the vaccine is not
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recommended for women over the age of 26 because it offered limited protection against HPV-related
diseases in clinical trials due to the fact that most women had already been exposed to one or more HPV
strains in their late teens or early twenties (CDC 2017d). However, research suggests that the vaccine
may be beneficial to older women, even those who are HPV positive. In fact, previously infected
individuals may benefit from vaccination by increasing antibodies and thus helping individuals clear HPV
more quickly and prevent re-infection (Muderspach et al. 2000; Scherer et al. 2016).

4.2.2

Non-Disclosure

A key element of safer sex is understanding one’s risk of acquiring an STI from your one’s
partner/s. To understand this, partners must be honest about their own sexual health and disclose any
positive STI statuses (Emmers-Sommer et al. 2010; Luchetti 2009). Past research indicates a large
portion of college students are unaware that disclosure is a component of safer sex practices (Luchetti
2009). However, most college students believe it is appropriate to disclose a positive STI status to one’s
casual or serious partner prior to having sex for the first time with this partner (Emmers-Sommer et al.
2010). However, these individuals cited many barriers to disclosure, including embarrassment and fear
of rejection by partners (Emmers-Sommer et al. 2010). Research also demonstrates that some
individuals knowingly misrepresent their STI status to their partners (Luchetti 2009).
Many women with HPV believe that their diagnosis will affect their sexual relationships, and
thus feel anxiety about disclosing their status to sexual partners (East et al. 2012; McCaffery et al. 2006).
Some women with HPV do not disclose their status to sexual partners because of shame and lack of
knowledge (McCaffery et al. 2006). Many women delay disclosure until just before having sex with their
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partner (Nack 2008). Individuals may decide to continue to have sexual relationships without disclosing
their STI status with their partner. Some women do not disclose their status until after having sex with
their partner, for fear of rejection (Nack 2008).

4.2.3

Inconsistent Condom Use

Researchers have long posited that consistent condom use is related to condom use selfefficacy, or an individual’s belief that they have the capabilities to control sexual situations (Artistico et
al. 2014; Bandura 1990; Bryan et al. 1997). Gendered condom use self-efficacy findings are mixed.
According to some research, women report lower condom use self-efficacy scores compared to men
(Farmer and Meston 2006; Roberts and Kennedy 2006; Wildsmith et al. 2010). This is because, for
women, condom use self-efficacy involves agency over sexual communication and negotiation with
partners (Artistico et al. 2014; French and Holland 2011). Other researchers posit that women have
greater condom use self-efficacy than men, are more likely to engage in safer sex communication, and
have a more active role in condom negotiation while men have a more reactive role (Allen et al. 2002;
Carter et al. 1999). Women claim that they feel capable of convincing their partner to use a condom
even if the partner does not want to and men are more likely to report being convinced to use a condom
if their partner wants to (Carter et al. 1999). However, women who perceive themselves to have less
decision-making power in their relationship are less likely to report consistent condom use (Pulerwitz et
al. 2002). Women’s intent to use condoms is also often derailed by their partner’s negative attitude
towards condoms (Farmer and Meston 2006; Roberts and Kennedy 2006). Men claim that they can
convince their female partners to have condomless sex even if she wanted to use a condom (Carter et
al. 1999). Women often report condom non-use because they believe condoms will decrease their
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partners pleasure during sex and they do not perceive themselves at risk for STIs (Roberts and Kennedy
2006).
Consistent condom use is also associated with perceived risk of STIs and intent to use condoms
(Bryan et al. 1997). However, most individuals’ perceived risk is lower than their actual risk for acquiring
an STI (Farmer and Meston 2006; Roberts and Kennedy 2006; Wildsmith et al. 2010). Individuals with
past STI diagnosis also do not perceive themselves at risk (DiClemente et al. 2002). They are not any
more likely to report condom use and are thus at risk for subsequent infection of STIs (DiClemente et al.
2002).
According to nationally representative research, only 23% of young adults aged 18 to 26 in
dating relationships used dual methods (condoms and hormonal birth control) and 26% used only
condoms (Manlove et al. 2011). Condom use decreased and hormonal contraception use increased in
these relationships as the duration and level of intimacy increased (Manlove et al. 2011). Individuals in
serious relationships are less likely to use condoms compared to single individuals (Emmers-Sommer et
al. 2010; Roberts and Kennedy 2006). Individuals in long-term relationships no longer view their partner
as an STI risk and as trust and a sense of security increases in a relationship, condoms are no longer
viewed as a necessary precaution (Emmers-Sommer et al. 2010; Manlove et al. 2011; Roberts and
Kennedy 2006).
Findings on the effectiveness of condoms in HPV transmission prevention are mixed. Some
studies show that condom use is related to a decreased risk for positive HPV status and development of
dysplasia (Manhart and Koutsky 2002; Winer et al. 2006). Research demonstrates that male-to-female
genital HPV transmission, specifically, is reduced by condom use (Winer et al. 2006). Other research
indicates an elevated risk for positive HPV status and development of dysplasia among women who use
condoms (Kjaer et al. 1997; Manhart and Koutsky 2002). This increased risk may be related to timing of
condom use (used after HPV was acquired) or to ineffectiveness of condoms on initial HPV infection
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(Manhart and Koutsky 2002). More recent research, however, posits that women whose partners use
condoms over 50 percent of the time are at reduced risk for acquiring a new HPV infection, both lowrisk and high-risk types (Winer et al. 2006). Studies also show that condoms and dental dams provide
protection against cervical cancer in women, HPV-related genital warts in both men and women, and
oral HPV infection in men (Edelstein et al. 2012; Manhart and Koutsky 2002).

4.3
4.3.1

THEORY
Information, Motivation, Behavior Model
The information, motivation, behavior (IMB) model is an appropriate theoretical framework

through which to investigate disclosure and sexual practice among the HPV positive. This model was
established to predict HIV prevention based on the concept that information, motivation, and
behavioral skills determine preventive behavior (Bahrami and Zarani 2015). The key elements of this
model applied to primary and secondary STI prevention include: STI knowledge related to transmission
and prevention techniques; motivation to change risky behavior and practice preventive behavior
related to one’s beliefs and attitudes; perception of personal risk of contracting and transmitting the STI;
perceived self-efficacy to perform STI prevention behaviors, such as condom and dental dam use,
condom negotiation, and disclosure of status (Bahrami and Zarani 2015; St. Lawrence and Fortenberry
2007).
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4.4

CURRENT STUDY
Disclosure and sexual behavior related to HPV diagnosis is a relatively new direction in research.

Most researchers have focused on the impact of condom use on HPV transmission (see: Manhart and
Koutsky 2002; Winer et al. 2006) or disclosure among individuals with a multitude of STIs including HPV,
genital herpes, and chlamydia (see East et al. 2012, Nack 2000). Through my research, I sought to
discover how an HPV + status influenced my participants’ sex lives, feelings about disclosure, and
reasons for not disclosing to sexual partners.

4.5

METHODS
Due to the fact that individuals with STIs qualify as a hard-to-reach population and recruitment

can be difficult (Dixon-Woods et al. 2001; Nack 2008), I employed purposive, facility-based sampling and
snowball sampling. I utilized key locations to find study participants (Magnani et al. 2005), such the
health clinic at a large public university in the Southeastern United States and multiple privatelyoperated gynecological clinics around a large metropolitan area in the Southeastern United States.
Commonly cited barriers to STI screenings include cost, privacy, language barriers, and perceived
discrimination at the clinical site (Tilson et al. 2004). Therefore, I chose to include clinics that offer free
or low-cost STI screening services to English and non-English speakers and that abide by antidiscrimination laws specific to patient admission and treatment. I also posted flyers around two major
universities, high-traffic pedestrian areas, and throughout diverse neighborhoods. Additionally, I gained
entry into online support groups for individuals with HPV13 to recruit group members for my study. In
order to allow for fully informed consent on the part of my subjects, I included accurate and
straightforward information about my research and its purposes.

13

http://www.dailystrength.org/c/HPV/support-group; http://hpvsupport.com/phpBB3/;
http://www.mdjunction.com/hpv; http://hpv.supportgroups.com/; http://www.hpvhope.com/support.html;
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I recruited my participants via advertisements (flyers) displayed and distributed at the recruitment
facilities. This discreet recruitment method is commonly used among STI researchers (see: Kosenko et al.
2012; East et al. 2012) so that interested parties can contact the researcher anonymously with any
questions. Multiple versions of the flyer were distributed with various photos of young girls and women
from different racial and ethnic groups on them in order to appeal to a diverse group of potential
participants. Each flyer contained tear-off tabs so that interested parties could easily obtain my contact
information. Additionally, each flyer included a Quick Response code. Quick Response codes are an
increasingly popular advertisement tool that can be scanned and read by smartphones (Shin, Jung, and
Chang 2012). The flyers contained a unique Quick Response code that linked smartphone users to my
online eligibility form. This eligibility form required users to enter their age and HPV status and then, if
eligible and interested in participating, their contact information was automatically sent to me.

4.5.1

Sample Demographics
I gave all of my participants pseudonyms to protect their identity. My participants included 23

women of various ages14. Six were in their 20s, eleven in their 30s, three in their 40s, two in their 50s,
and one over 60 years old. Sixteen of the 23 participants grew up in a two-parent family; three had a
single parent; three had divorced parents and stepparents in the home; and one had divorced parents
that never remarried. Twelve of my participants grew up in the Southeastern United States; six grew up
in the Northeast; three grew up in the Midwest; and two grew up outside of the United States. Fifteen
of the participants resided in the Southeastern U.S. at the time of their interviews with three living in
the Northeast; one in the Southwest; two in the West; and two outside of the United States. My sample
was a highly educated group, with 10 of my participants having obtained a graduate degree, four in
14

My sample originally included 25 individuals, but after the interview, I determined that two no longer qualified
to be included, due to their type of HPV. Both of those original participants had HPV that manifested as skin warts
on the hands and feet – a condition that is not considered a sexually transmitted infection and is not related to
reproductive issues or cancers.
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graduate school at the time of interview, six obtaining a terminal Bachelor’s degree, one currently in
undergraduate school at the time of interview, one having had some college education, and one having
a GED as highest level of education. Regarding occupation, eight worked in health and medicine, four in
education, three in law, three in the arts, one in business administration, one in marketing, one in
plumbing/engineering, and two as current students. The majority of my participants were white (n=17,
73.9%), five (21.7%) were black, and one (4.35%) was multiracial. Ten of my participants were single at
the time of interview, 8 were in a committed relationship, and 5 were legally married. In terms of
gender identity, 22 of my participants identified as women and one identified as gender queer. In terms
of sexual orientation, 18 classified themselves as heterosexual, one as lesbian, and four as bisexual.

4.5.2

Interview Method

Although many past researchers have used surveys to analyze knowledge, awareness,
and attitudes regarding HPV and the vaccine, other researchers find that semi-structured interviews
allow participants to explain their personal experiences of dealing with STI diagnosis and what this
diagnosis meant to them (see: Gerend and Magloire 2008; Lee and Craft 2002). Interviews of HPV+
participants, compared to survey research, are more likely to foster discussion of actual lived
experiences related to living with HPV and disclosure to others, and stigma.
As a feminist interviewer, I was cognizant of my role as a researcher and my potential
source of authority during the interview process (Hesse-Biber 2007). In order to diminish the
hierarchical relationship between researcher and participants, after each interview, I shared relevant
aspects of my own biography (Hesse-Biber 2007) and experience with HPV. I strove to be reflexive and
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to consider how my biography, values, and attitudes influenced the research process (DeVault and Gross
2012; Hesse-Biber 2007). As a woman with HPV, throughout the interview and analysis stages, I
reflected on how my attitudes regarding the disease impacted my choice of interview questions and my
interpretation of participants’ responses (DeVault and Gross 2012). For example, I was motivated to ask
about disclosure to sexual partners because of my own decision-making about disclosure. My personal
experience also helped me understand the participants’ motivations to disclose or withhold this
information from sexual partners.
Interview topics included: what participants knew about HPV post-diagnosis, to whom they
disclosed their status, reasons for their disclosure and non-disclosure of status, and how their diagnosis
impacted their sex life, if at all.

4.5.3

Analysis
I conducted, recorded, and transcribed all of the interviews. I imported all transcribed materials

into NVivo and analyzed them using a grounded theory approach. I chose this analytic method because
it is well suited for understanding social processes not yet commonly researched (Hutchison et al. 2010).
And, as noted above, there have been very few qualitative studies on the lived experiences of
individuals with HPV. From my transcription and pre-analysis coding, I identified a few themes that I
wanted to further investigate related to consequences of HPV: “feelings about HPV,” “impact on sex
life” and “disclosure to sexual partners.” I analyzed the transcripts using the triadic coding scheme of
open, axial, and selective coding (LaRossa 2005). During open coding, I identified major themes related
to consequences of HPV, impact on sex life and disclosure to sexual partners, and deciphered what each
concept represented (Lofland et al. 2005; LaRossa 2005). In the context of their diagnosis, each
participant mentioned how their diagnosis impacted their sexual relationships. I then reviewed the
concepts for similarities and variations, assigned them to categories, and identified the most salient
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categories (Corbin and Strauss 1990). I analyzed participant feelings and knowledge post diagnosis,
whether or not participants disclosed their status to past and present partners, why they did or did not
disclose, and how their diagnosis impacted their sex life.
In the axial coding stage, I analyzed the categories to determine how and why they differed
among the participants, by focusing on the context, strategies, and consequences associated with each
category (Corbin and Strauss 1990; LaRossa 2005). I analyzed relationships between participants’
experience with the diagnosis, disclosure and sexual behavior. Finally, I moved on to the selective coding
stage of my analysis, where I decided which categories were most representative of the central
argument of my analysis (Corbin and Strauss 1990; LaRossa 2005). I found the relationships of (1)
feelings and knowledge about HPV impacting sexual behavior and (2) feelings and knowledge about HPV
impacting disclosure of status to sexual partners to be most informative in this study.

4.6

FINDINGS

4.6.1

HPV & Prevention Knowledge

My participants had a variety of HPV types and stages of cervical dysplasia. Cervical dysplasia
indicates abnormal cells on the cervix surface that may clear or develop into cancer depending on the
severity of the dysplasia (Mayo 2017). Six did not know whether their type was high-risk or low-risk or
what level of cervical dysplasia they had at the time of interview. Without this knowledge, these
individuals were unaware of the potential risk they may have been causing their partners or their
partners’ future partners. Three individuals had an HPV strain that led to the development of anogenital
warts at their vaginal opening, inside their vagina, or inside their cervix. Anogenital warts are easily
transmitted through sexual contact and thus, potentially consequential for sexual partners. Five
participants stated that they had low-risk HPV, which is asymptomatic, does not lead to cancer, and
usually clears from the body within a few years. This type of HPV poses little risk to one’s sexual
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partners. One participant knew she had a high-risk strain of HPV that was more commonly linked to
cervical cancer. Two individuals had mild dysplasia (level 2) and four participants knew they had
moderate to severe dysplasia (level 3 or 4). The higher the level of dysplasia, the more likely it will lead
to cancer if left untreated. Two of my participants had developed anal cancer by the time of our
interview. This type of cancer is rare in women, but can develop from severe cervical dysplasia. Although
most high-risk strains of HPV that lead to higher levels of dysplasia do not lead to cancer in males, male
partners can acquire a high-risk strain and then transmit it to future female sex partners or re-infect
their current partner once it has cleared from her body.
In another article, I analyzed my participants’ HPV knowledge pre and post-diagnosis. Eight
participants remained unaware of the high prevalence of HPV after their diagnosis. Nineteen of the
participants did not know that HPV could be contracted through skin-to-skin contact and did not require
penile-vaginal or penile-anal penetration. Only two individuals explicitly stated that condoms would not
completely protect a person from contracting HPV. They stated: “there is no 100% and I think it is a false
sense of security people do get from using condoms” (Riley), and “people probably don't know that HPV
is transmitted by skin-to-skin contact, and you can use condoms but it is not just about covering an
orifice. You would have to have sex with a rubber suit on” (Colleen). Only two more participants knew
that HPV could be transmitted from skin-to-skin contact and did not require penetrative sex. Many of
my participants lacked this knowledge of HPV transmission and thus, did not use recommended
protection, such as condoms and dental dams.
Despite most participants not having a complete understanding of how HPV is transmitted, nine
of my 23 participants voiced concern about transmitting HPV. Seven participants worried about infecting
their current partner at time of diagnosis. One participant was afraid of transmitting HPV through oral
sex when her boyfriend had a toothache, “he got a horrible toothache…he was really worried. He was
like I don't know what it is, what if it is oral cancer? I was like, ‘you don't have oral cancer’... and he was
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like, ‘HPV brings oral cancer.’ So I was concerned about oral sex because we did not use any protection
with that” (Summer). Another worried about transmitting to a serious partner, “I felt a little guilt around
that ... exposing him. I really loved him” (Phoebe). One participant expressed guilt about possibly having
transmitted HPV to past sexual partners. She said that she may have unknowingly infected past partners
due to the dormant nature of HPV, “who knows how long I have been carrying it and not showing
anything -- and, second of all, who I may have affected along the way. I just kind of feel like a jerk. But I
don't know there is really anything I can do about it now, just be more careful and not let it happen
again” (Amber). Due to a lack of HPV transmission knowledge, the dormant nature of HPV, and the
inability to have male sex partners tested for HPV, many of my participants were concerned about
transmitting HPV to their partners, but felt unable to control the situation.
Although the HPV vaccine reduces one’s risk for infection and thus prevents the spread of
disease, sixteen of my participants were not vaccinated. Among those not vaccinated, the most cited
reason was that the vaccine was not available to them pre-diagnosis. Seven participants stated that they
would have gotten the vaccine if that had been an option for them. These participants were either
diagnosed before the HPV vaccine was manufactured or they were diagnosed when they were past the
recommended vaccination age cut off of 26. One complained about the vaccine age cut off stating: “this
really sucks because I would have taken the HPV vaccine. I get that they want to target people before
they become sexually active and by 40, most people have had it, but clearly I am the outlier” (Colleen).
Another reflected on the availability of the vaccine for younger aged women stating, “when they [HPV
vaccines] came out I was already past 26, I was like, damn it, they [younger women] get it so much
easier now” (Riley). Although the vaccine is recommended for younger men and women and not
covered by insurance past the age of 26, many of my participants could have opted to pay out-of-pocket
for it. This was information that most of my participants were unaware of at the time of interview.
Without this information, they were unable to utilize this method to prevent their own infection and
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transmission to their sex partners. Three of my participants opted to receive the vaccine after testing
positive for HPV. They used it as a method to prevent against “flare-ups”, developing cancer, or
acquiring another strain of HPV that caused warts. Two received the vaccine at the recommendation of
her doctor, while another had to insist on getting the vaccine. She recalled that many people in her life
said, “you already have HPV; this [the vaccine] is not going to help you” (Theresa). She, however,
decided to get vaccinated anyway.

4.6.2
4.6.2.1

Impact on Sexual Behavior
Risky Sex

Twelve participants, were in a monogamous relationship at the time of interview. All of these
individuals disclosed their HPV status to their monogamous partners. Nine of these individuals did not
use barrier methods (condoms, dental dams) with their monogamous partner. Two of these participants
did not use barrier methods because they did not have sexual intercourse with their partner. One of
these abstained due to pain associated with intercourse from chemotherapy and scar tissue. The other
participant who did not have intercourse, chose to abstain as a protective measure until she and her
partner were treated for HPV. One participant did not use barrier methods because HPV had cleared
from her body before beginning her current monogamous relationship.
Six participants did not use a barrier method with their monogamous partner, were still HPV+, and
continued to have sexual intercourse. Although some of the participants used a condom during their
first sexual encounter with this partner, none continued to use condoms due to testing negative for
other STIs, being on birth control, or trusting that their partner did not have any other STI. One stated
that her reason for not using condoms was because she “assumed he probably already had it” (Carla).
This individual was not concerned about passing HPV on to her partner because she knew how common
it was and did not understand the potential health consequences for men. Another cited her trust in her
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partner as a reason to not use condoms: “you can never know 100% but we have been together 12
years and I trust him so ... as far as I know, we have only ever been sexually active with one another
since we were like 17. Because of that we knew fairly early on in our relationship that this was a longterm thing and, um, so we weren't super concerned about safer sex practices. I was always on some
form of birth control but we did not worry a lot about STIs because I think we felt comfortable in each
other’s commitment” (Leah). This individual worried about transmitting to her partner and asked him to
see a doctor. Once the doctor told them that her male partner had no external physical abnormalities,
so they assumed he was HPV free. Another participant stated that she only used condoms with her
current partner during their first sexual encounter and did not consider using condoms post diagnosis,
“because I knew I already had it and even if I got it from someone else, I had been sexually active for
about 6 months with my current partner so either I had it and for sure now he has it or I just got it from
him anyway” (Ava). Another stated, “I was sure we both already had it from years and years of
unprotected sex…. Theoretically if [my husband] had gotten it too, we could just keep giving it to one
another” (Andrea). These participants’ experience highlight that an inability to test men and assumed
positive status based on high prevalence can lead to transmission and even reinfection between
partners.
Eleven participants were single or in non-monogamous relationships at the time of interview. Three
of these participants did not use condoms, but did disclose their HPV status to some of their partners.
One of these participants told a few of her recent sexual partners about having HPV, but did not practice
safer sex with them because they did not ask to use condoms once they knew about her status. When
telling one partner her status she told him “how common it was. That men are the carriers. That he
probably already had it anyways” (Leslie). One participant told her primary partner right after diagnosis,
but they did not start practicing safer sex: “I went home and told my partner. We did not start using
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condoms” (McKenzie). She did, however, mention practicing safer sex with her other sexual partner,
although she did not disclose her status to them.
Three of the participants who did not use condoms also did not disclose their HPV status to their atrisk partners. One participant disclosed her status to her husband, but has not disclosed to any new
partners since their divorce. She did not use condoms with her husband or the more recent partners.
She demonstrated that this was related to a lack of knowledge, “there was not a lot of information
about that [HPV in men] and by the time there was information we were divorced” (Katherine). Another
individual did not disclose her status or start using condoms with a casual sex partner because, “we had
already been having sex and already not using a condom at that point so I was like... he's screwed
already…. It was only after both of us tested for STDs that we started not using condoms, but again, I
didn't tell him about the HPV” (Whitney). One participant, who did not tell some of her recent sexual
partners, cited disliking condoms as her reason for not using protection against transmitting HPV:
“condoms suck. Nobody wears condoms and if you do you are not having very good sex because
condoms are lame. Having HPV has not changed anything. Like I really don't use condoms and I don't
think HPV merits that” (Emily). She asserted that she was having casual sex with people whom she
trusted, “like if I was having random stranger sex I would of course wear a condom and probably not
even have sex with them. But condoms just suck. That is it. I don't like them. And just because I have
HPV, I won't use them” (Emily). The lack of barrier method use among these participants at least in part
resulted from misinformation about how HPV is transmitted, how men are impacted by HPV, and the
inability to test men for HPV.

4.6.2.2

Safer sex

Fourteen participants used barrier methods with some of their sex partners who were at risk for
contracting HPV. One participant recalled using dental dams and gloves with her current female partner:
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“I did start a relationship many months later. I have only had sex with women and I have a female body
so I had never had to use a dental dam or gloves, and I was like ‘are you freaking kidding me’... it was
not as much fun. And my girlfriend was great at the time, she was like ‘we will figure it out, it will be
fine’. I was like ‘seriously? Gloves?’...but she was understanding. And until we were sure of it - that the
HPV had been cleared up and I was ok… yeah it changed things drastically” (Jessie). Thirteen participants
specifically mentioned using male condoms. Eleven of these participants continued using condoms after
diagnosis, a practice they started before knowing they were HPV positive. Two participants who used
condoms stated that their diagnosis motivated them to practice safer sex than they had previously. One
said, “I was having it [safer sex] more often after the diagnosis” (Tiffany).
Four of the participants who continued or began to use condoms post diagnosis, disclosed their
status to all of their at-risk partners, one disclosed to some of her casual partners, and another disclosed
only to her primary partner. One stated, “up until we got married we always used condoms. I went on
birth control and it did not suit me so we always used condoms not to have children. So using them
protected us I guess from passing it [HPV] back and forth” (Summer). One participant vaguely alluded to
having safer sex, “[I am] more careful, but that was something that kind of happened naturally with
growing up and having more respect for myself. It's [HPV diagnosis] just kind of reinforced that… in
terms of being promiscuous or sleeping around, those days are over. Not just because of that
[diagnosis], emotionally I have grown beyond it” (Amber). This individual did not explicitly state that her
safer sex practices included using condoms or other barrier methods.
Four of the participants who did not disclose their status to sexual partners stated that they
practiced safer sex post diagnosis. Two of these participants used condoms with every sexual partner
while HPV positive. One stated that since her first boyfriend, every other encounter has been “100%
condoms every single time, non-negotiable” (Collen). Another stated that she, “used condoms with
those sex partners.... It was a standard for me at the time. I wasn't on birth control so I would not have
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not used condoms. It wasn't about HPV… just general safe sex” (Phoebe). One participant noted that she
did not use condoms every time she had sex after diagnosis, just more often. This participant felt that
her more frequent condom use warranted not disclosing her status, “I was being more cautious though,
and using more condoms too. I was like, ‘ok, if we are using condoms I don't need to tell you’” (Tiffany).
Although fourteen of my participants used barrier methods with some or all of their sex
partners at risk for contracting HPV, thirteen of these only used condoms. Condoms alone do not
prevent transmission of HIV because it can be contracted through skin-to-skin contact and does not
require penile-vaginal or penile-anal penetration. A more effective way of preventing HPV transmission
would have been to use multiple barrier methods, such as condoms during vaginal, anal and oral sex and
dental dams during oral sex. Only one participant used dental dams, however, and she stated a common
barrier to using this method: “I mean this is so clinical. It was really not fun” (Jessie).

4.6.2.3

Less Sexual Activity

Ten participants, in total, recalled having less frequent sexual encounters after their diagnosis. Five
of these had disclosed their status to their current sexual partner. Those who had disclosed cited both
the diagnosis and the related treatments as sources for their decreased sexual activity with their
partners. One participant mentioned thinking negatively about sex because of the diagnosis: “I
remember right around the time feeling a little less horny, like I had less desire to have sex because I
was like, this is what happens when you have sex, this kind of fucked up shit” (Summer). Another cited
fear of transmitting HPV to her female partner and acquiring it again as a reason to avoid sexual
intercourse. To protect each other, they “primarily just [do] not having sex…We make out sometimes
and feel each other but we don't get anywhere close that things could be exchanged” (Amber). One
participant that linked her related treatments to decreased sexual activity stated that her partner was
supportive of her during this difficult time, “because of the scar tissue from the surgeries [multiple cold
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knife conizations15], my cervix is closed the same way a woman in menopause cervix is closed... It has
affected me because most of the time sex is painful. My fiancé, he loves me to death so he works with
me and doesn’t pressure me about it or get upset about it. He understands. But it is definitely
something that impacts me sexually in being confident as well during sex” (Kaylee). Another said that
being no longer sexually active was a consequence of HPV-related cancer radiation, “because of all of
this and the after effects of radiation, we are no longer intimate with intercourse. So I am not able to
partake that way” (Theresa). However, she mentioned that she would also have stopped being intimate
with her partner because of her positive status alone: “It [sex life] would probably change because I
would not have been comfortable having unprotected sex. I couldn't sit there and be in a relationship
being a detriment to somebody's health, basically” (Theresa). Another individual whose sexual activity
lessened at time of diagnosis and during treatment stated “Our sex life did start to change - I think... we
started having sex less frequently… We would start to have sex and I would just not want to keep going
and I would stop feeling it... for whatever reason would be turned off...I remember especially after
getting the colposcopy I was not feeling well and was not interested in having sex” (Erica). All of these
participants disclosed their status to their sex partners and felt supported in their decision to have less
frequent sex or abstain due to their status and/or consequences of treatment.
Five participants who did not disclose their status to their current partner, recalled participating in
less sexual activity since their diagnosis. Two of these participants mentioned that their sexual activity
decreased or stopped completely after diagnosis because of their status. One explained how her
diagnosis impacted her sex life, stating: “the desire [to have sex] was there but the will definitely
decreased…. We don't do it very often at all and I avoid it a lot…. I am just going to hold out as much as I
can until next year when I get my next pap smear. Yeah try to space it out [sex] as much as possible”

15

Cold knife conization surgery removes a portion of abnormal cervical tissue with a scalpel for examination. This
method causes significantly more bleeding than LEEP and often requires general, epidural, or spinal anesthesia.
The use of this method of conization has decreased since LEEP became widely accepted (Nyirjesy 2015).
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(Kendra). One participant who was single at the time of the interview also felt her sex life was impacted
by diagnosis, “Yes, right afterwards yes. I was tested in November and I don't think I was sexual at all for
a couple of months. It was just a bummer.... It makes you not interested” (Whitney). Three of the nondisclosing participants did not feel their diagnosis impacted the frequency of their sexual activity at time
of diagnosis, but recalled how HPV-related procedures and recovery caused them to be less sexually
active. One recalled, “the fact that I needed to take 6 weeks after the procedure and not be available… it
made me feel upset because it made me feel like my body was not cooperating with me” (Candace).
Another stated, “it took a really long time to heal. For the longest time I had - they weren't scars but you
could see - and the skin was really thin so for a really long time sex hurt. I could not have sex for long
periods of time after that but now I am back to normal but it too a really long time to heal because it is
such vulnerable skin down there. That was very difficult and uncomfortable” (Emily). One participant’s
sex life was not impacted at diagnosis, but has since become sexually inactive due to the HPV and anal
cancer-related procedures stating that future sexual partners are “highly unlikely. I don't have much to
work with - that makes it somewhat difficult” (Katherine).
Ten of my 23 participants’ sex lives were impacted by having HPV. Many reported painful sex, long
recovery from HPV treatment, and long-term consequences of treatment as the main reasons why their
sexual activity lessened or stopped completely. Those who disclosed their status to partners felt
supported in their choice to have less sex. Some of my participants avoided sex with their committed or
casual partners who were unaware of their status. This avoidance was often rooted in their reasoning to
non-disclose, as discussed below.

4.6.3

Non-Disclosure

Sixteen of my 23 participants did not disclose their HPV status to one or more of their sexual
partners. Most of the sexual partners they did not inform were at risk for acquiring HPV because they
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were recent or current sexual partners. Reasons for non-disclosure varied from merely never discussing
STIs, to avoiding embarrassing and hard conversations, to believing their partners were at little risk for
contracting HPV from them.

4.6.3.1

Difficult Conversation

One individual explained that they did not disclose to their current sexual partner merely because
they never spoke about STIs. She came to that realization when stating, “wow, 16 years and we have not
had that kind of conversation” (Tiffany). Six participants, however, purposefully withheld their positive
HPV status from current or past sexual partners because they believed it would be a difficult
conversation to initiate. Two individuals decided not to mention their status because they feared sexual
rejection from their partners, “I did not want to risk them having a bad reaction and not want to have
sex with me. I did not want to deal with it or disclose so I did not disclose at that time” (Phoebe).
Another stated, “it's an embarrassing thing to have…. What is telling him going to do, except probably
have him not see me anymore?” (Whitney). One participant, in a non-monogamous relationship, was
too embarrassed to disclose to any secondary or tertiary sexual partners, “I think it [reason for nondisclosure] is embarrassment and shame. It has less to do with rejection. I don't really care about that
from those folks. I just don't think it is necessary. I think that is not a rational response. This part of me
just doesn't want to tell anybody” (McKenzie). One individual disclosed to their current sex partner, but
not to past partners at risk because it would be a “difficult” conversation with these past sexual partners
(Summer). One did not disclose her status because she believed it was a result of infidelity, “it
[disclosure] would have been me telling him I got HPV from cheating on him” (Phoebe). Another
participant does not plan on telling future sex partners, explaining that conversation was too intimate:
“do I feel like I need to talk about it with someone that I am just having sex with? No, because I don't
feel like it is important. It is more deep than I want that relationship to be. I just want someone to come
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hang out, we have sex, you can go” (Emily). All of these participants actively avoided having a
conversation with some of their at-risk sex partners about their positive status, but some of them did so
because they assumed their partner was also HPV positive.

4.6.3.2

Little Risk to Male Partners

Over half (14 of 23) of my participants did not disclose their HPV status to at least one of their male
sexual partners because they believed there to be little risk of new transmission or few negative physical
consequences for their male partners. Four individuals chose not to tell their sexual partners about their
HPV because they assumed the partner had already contracted it, “I never talked to sexual partners
before we have sex like ‘I have HPV, just want to let you know’ because they probably have it too”
(Emily). Another recalled, “I remember offhandedly being like ‘well obviously I have HPV so obviously
you do too’” (Phoebe). One stated, “the people that I have had sex with are around my age so I am sure
that everyone has HPV and there is literally nothing that you can do about it” (Colleen). Another said she
would not tell her sex partner “because he is already a carrier there is nothing I can do about it” (Ava).
One participant thought it was too late to prevent transmission and therefore did not mention it to her
partner, “we had already been having sex and already not using a condom at that point so I was like...
he's screwed already…. It was only after both of us tested for STDs that we started not using condoms,
but again, I didn't tell him about the HPV…. I'm a jerk” (Whitney). All of these participants decided to not
disclose their status to sex partners because they assumed their partner had it previously or had already
contracted it from them. They felt there was little to gain for either partner by disclosing their status.
Three participants did not think to tell their male partners because they knew it was something
men could not get tested for, “there is no way to easily test on a man. I just don't think it is that big of a
deal” (Emily). One individual stated, “I think it was a matter of just did not think to. I know that sounds
odd but yeah. I guess probably because male partners really can't get tested for it” (Katherine). Another
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stated that disclosure is unnecessary for this reason, “If I called someone now and told them that [I had
HPV] they would laugh at me… I really do feel like that because really what are you supposed to do? He
can't... he won't ever know if he has it” (Ashley). Four individuals thought HPV would not impact male
partners and thus did not disclose, “it is not going to affect them in any real way except give them this
random information that they can do nothing with... what is the point” (Ashley). Another did not feel
the need to mention it to her past male partners, “I don't really see the point in doing so [disclosing]
because the two people I am thinking of are both men and they wouldn't have any symptoms if they
have what I have” (Amber). One said she did not disclose to her partner “because it is not going to affect
him” (Ava). One of these participants did not consider telling their partner, “I did not even think about it.
This is the first time I have thought about it… because it is transmittable, right?” (Janelle). All of these
participants did not feel compelled to disclose their positive status because they knew their male
partners would not be able to find out their own status. One participant, who disclosed only to her
current sex partner, asked the diagnosing doctor for advice about disclosing to sexual partners and
recalled, “I did ask him [doctor] questions about if it would impact my partner because my boyfriend
was worried about it as well. The gynecologist wasn't as concerned about how it would affect partners
unless they were female partners. He was like, ‘well, you can't test on guys so there is nothing I can do
or advise on that’” (Erica). This patient-provider exchange supports my participants’ motivations to not
disclose to male sex partners.
Three participants did not tell their past sexual partner because they were having safer sex. One
felt no need to tell her partner because they were using condoms and she wanted, “just not to have to
deal with the whole process of explaining the diagnosis and whether the person may have been familiar
with it or understood it or anything… just to not have to deal with that... not necessarily the proper thing
to do” (Tiffany). Another stated, “that [disclosing] is an awkward conversation starter and I knew that
we were practicing safe sex and it wasn't a huge risk” (Kendra). One individual similarly explained,
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“Unless they asked if I had an STD before I didn't really say. I didn't really think it was a big deal. Maybe I
was wrong in that thinking but since we were using condoms and it was the cervical cancerous kind, I
was not really concerned about my male counterpart” (Leslie). As mentioned above, these participants,
while aware of the protective effect of condoms, were not aware that using additional barrier methods
would decrease the likelihood of transmitting HPV.
Six individuals mentioned that they would disclose other STIs that were more serious in their
eyes. One participant compared it to other STIs when rationalizing non-disclosure stating, “HPV is very
different. If you have any other kind of STD… a disease is different than an infection. A disease is really
fucked up. When you have unprotected sex with someone you are taking a risk of faith on them and
they on you” (Emily). Another explained, “I think you know with the herpes HSV the fact that you can
give it to someone else and it is a lifelong thing and doesn't clear up…. it is also cosmetically not pretty. I
would definitely disclose that or my sexual behaviors would change. If it was HPV with genital warts yeah I would have said something” (Leslie). Another said, “it still did not occur to me to tell about HPV,
but I will disclose about HSV” (Candace). One individual stated, “I was thinking in my mind that if the
results were positive [for HSV] that I would call and tell him [sex partner] because he was the only one I
had been with since then but this [HPV] did not seem that serious, like I did not need to make a phone
call. This one [HPV] does not seem so scary because she [nurse] told me it would go away” (Janelle).
Another participant, who had not disclosed to their most recent partner, mentioned how other STI
diagnoses would impact disclosure and sexual behavior. They stated, “if I was diagnosed with HSV2 I
would feel shitty about that even though I know how prevalent that is too… I would feel a responsibility
to disclose and I don't want to do that. If I were diagnosed with gonorrhea or chlamydia I would think
that sucked, but it would not be a big deal because I would take the antibiotics and be done with it. I
would probably not have sex until it cleared. I would probably tell my current sexual partner and hold
off until it cleared. I would not have sex with a new partner while under treatment for chlamydia”
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(Phoebe). Another said, “if it was something that would affect my health and if it happened to other
women and would affect their health severely - like if it was something like I don't know much about
other STDs but definitely like AIDS or like - things that cause long symptoms I would have gone back and
informed” (Ava). All of these participants felt that HPV was not serious enough to warrant diagnosis
disclosure. Again, all 14 of the above participants did not disclose because of a lack of knowledge
regarding HPV’s impact on men. They did not believe they were putting their male sexual partners at
risk for HPV or HPV-related consequences, such as genital warts, penial, or throat cancer.

4.6.3.3

Clearance and Prevalence

Two participants did not disclose their HPV status because they knew it was highly prevalent, “I
think I was like well it is so common it does not matter. It wasn't something I thought of… like a thing I
need to disclose” (Phoebe). Another stated, “I never thought to disclose that I had it to partners. It
didn't even occur to me. It was just abnormal cells and basically everyone has it is” (Candace). Two no
longer disclosed because HPV has cleared from their bodies, “in the last year it has been clear so I
stopped telling partners” (McKenzie). Another who no longer tests positive for HPV stated, “I think it is
irrelevant if it is not a current thing” (Riley). These two participants disclosed their status to most of their
sex partners when they still tested positive for HPV, but felt that they no longer had it to transmit and
thus, no longer needed to disclose.

4.6.3.4

Guilt

Three participants expressed some guilt due to their non-disclosure. One stated, “if I feel bad about
anything it is not disclosing [to the secondary and tertiary partners]” (McKenzie). Another recalled, “I
didn't tell him about the HPV… I'm a jerk (Whitney). Another who believed she acquired HPV from sex
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outside of her relationship stated, “I am sure I felt a little guilt around that - exposing him[boyfriend]. I
really loved him” (Phoebe). Despite feeling guilt for non-disclosure, these participants chose not to
disclose for multiple reasons: it was a difficult conversation to have, believed there was little HPV risk to
men, and knew HPV was extremely common. Two of these participants did not use condoms with their
at-risk partners.

4.7

LIMITATIONS
Past qualitative research on HPV has relied on non-diverse samples of primarily white, college-

educated women (see: Kosenko et al. 2012, Nack 2008). Although I sought to reveal the stories of a
diverse sample in terms of ethnicity, race, and educational attainment level, my sample was more
homogeneous than initially intended. My sample included cis-gender and gender non-conforming
women from different racial and ethnic groups ranging in age. However, I was unable to include
participants of varying levels of educational attainment. This may have been a result of my sampling
method. However, I also believe it is due to the fact that women with lower socioeconomic status and
less education are less likely to have regular gynecological appointments and routine Pap tests,
compared to their more educated peers (Behbakht et al. 2004; Katz and Hofer 1994). Without regular
visits to the gynecologist and routine Pap tests, women are much less likely to know they are HPV
positive. Therefore, individuals who saw my flyers may have thought they did not qualify because they
did not know their positive status.

4.8

DISSCUSSION
According to past research, individuals with HPV are often unaware of symptoms, risk of

transmission, and recommended lifestyle changes (Perrin et al. 2006; Sharpe et al. 2006). Use of barrier
methods (condoms, dental dams) and disclosure of HPV status are two prevention strategies that can be
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used by individuals who are HPV positive. These behaviors, while not 100% effective at preventing the
transmission of HPV, can prevent initial acquisition, transmission to partner, and re-infection among
partners. Although many Americans are unaware of the potential of HPV re-infection after clearance, reinfection with the same HPV type is a common occurrence (Trottier et al. 2010). Many women with HPV
do not disclose their status to partners because of this lack of knowledge and feelings of shame for
having an STI (East et al. 2012; McCaffery et al. 2006; Nack 2008). Some individuals with HPV, according
to past research, do not use barrier methods to protect against transmission to their partners (Nack
2008).
According to the information, motivation, behavior (IMB) theoretical model, STI prevention
techniques are used by individuals who are well informed, perceive themselves to be at risk, are
motivated to change their risky behavior, and feel capable of using prevention strategies (Bahrami and
Zarani 2015; St. Lawrence and Fortenberry 2007). In order to participate in STI risk-reducing behavior,
according to the IMB model, individuals must be informed about STI risk-reduction (St. Lawrence and
Fortenberry 2007). Specifically, people need to be knowledgeable about STI transmission and
prevention methods (Fisher and Fisher 1992; St. Lawrence and Fortenberry 2007). Many individuals are
unaware that STI disclosure is a component of safer sex practices (Luchetti 2009). The majority of my
participants did not disclose their HPV status to one or more of their sexual partners. According to past
research, much of the general population is unaware of their risk of acquiring and transmitting HPV
(Blake et al. 2015; Gerend and Magloire 2008; Sandfort and Pleasant 2009; Ratanasiripog et al. 2013).
Although some of my participants were concerned about transmitting HPV to their partners, the
majority of them did not know that HPV could be transmitted from skin-to-skin contact. Past research
indicates that people are also misinformed about how HPV impacts men and believe there are no HPVrelated health threats for men (Sandfort and Pleasant 2009). Fourteen of my participants who did not
disclose to a male sex partner were unaware of the HPV-related health consequences for men.
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Individuals who participate in oral sex often do not understand STI transmission through oral sex, and
are unaware of prevention methods (dental dams) to use during oral sex (Chambers 2007). Only one of
my participants used dental dams to protect against transmission. None of my heterosexual participants
used this barrier method to prevent transmission through oral sex.
Knowledge alone is not sufficient enough to change behavior, according to the IMB model
(Fisher and Fisher 1992). Informed individuals must be motivated to act on their knowledge and change
their risky behavior (Fisher and Fisher 1992; St. Lawrence and Fortenberry 2007). They must have the
strong desire to initiate and maintain prevention strategies, such as condom use, dental dam use, and
status disclosure. This motivation is, in part, related to one’s perceived susceptibility to risk and
adherence to social norms surrounding prevention techniques (Fisher and Fisher 1992). Consistent
condom use is associated with perceived risk to STIs (Bryan et al. 1997). However, many people often do
not perceive themselves at risk for HPV (Gerend and Magloire 2008; Sandfort and Pleasant 2009;
Ratanasiripong et al. 2013; Blake et al. 2015). Many of my participants were unaware of the high
prevalence of HPV, even after their own diagnosis. Normative behavior related to condom use differs for
individuals in committed relationships compared to those in casual sexual relationships. Individuals in
serious relationships are less likely to use condoms, compared to single individuals, because as trust and
a sense of security increases in the relationship, condoms are no longer viewed as a necessary
precaution (Emmers-Sommer et al. 2010; Roberts and Kennedy 2006). The majority of my participants in
monogamous relationships did not use condoms or other barrier methods to prevent HPV transmission
and reinfection. Many of these individuals used condoms at the beginning of their relationship, but
discontinued use once they trusted their partner, had been tested for other STIs, or went on hormonal
birth control. Motivation to disclose status, among those with HPV, is often thwarted by fear of
rejection, embarrassment, and feelings of shame (East et al. 2012; McCaffery et al. 2006; Nack 2008).
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Some of my participants withheld their status from partners because they were embarrassed or worried
that their partner would reject them.
In order for a knowledgeable, motivated individual to actually change their risky behavior, they
must have the skills to perform the recommended preventive behaviors (St. Lawrence and Fortenberry
2007). These skills include obtaining a vaccine, correct condom use, sexual communication, condom
negotiation, and a sense of condom use and condom negotiation self-efficacy (Fisher and Fisher 1992).
Individuals must feel that they are skilled enough to act on their knowledge and motivations in order to
change their risky behavior or initiate and maintain preventive behavior (Fisher and Fisher 1992). HPV
vaccination intention and uptake is lower among older adolescents and college age women due to
vaccine safety concerns, side effects, insurance issues, cost, low perceived risk, and belief they are too
old to receive the vaccine (Laz et al. 2013; Patel et al. 2012). Most of my participants never received the
HPV vaccine because they did not qualify for insurance coverage based on age, were diagnosed before
the vaccine was readily available, or were unaware of the vaccine before diagnosis. In support of
previous research (see: East et al. 2012; McCaffery et al. 2006), some of my participants were unable to
disclose because they were embarrassed, feared sexual rejection, and did not feel confident in having
the difficult conversation about their status. Actual condom use is related to condom use and
negotiation self-efficacy (Bryan et al. 1997). In some studies, women report lower condom use selfefficacy scores than men and often report not using condoms because their male partner does not want
to (Farmer and Meston 2006; Roberts and Kennedy 2006; Wildsmith et al. 2010). Other researchers,
however, posit that women have greater condom use and condom negotiation self-efficacy (Allen et al.
2002; Carter et al. 1999). Some research demonstrates that women with HPV become more assertive
about condom use with their partner post diagnosis to avoid transmission and re-infection (Nack 2008).
Some of my participants practiced safer sex post diagnosis because they feared transmitting it to their
partners. Many, however, felt incapable of preventing HPV transmission through the use of condoms
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because they assumed their partner already had HPV or they knew that condoms would not completely
protect their partner.
I found, in support of past research (see Bertram and Magnussen 2008; Kosenko et al. 2014;
Perrin et al. 2006; Sharpe et al. 2006), that many individuals with HPV are misinformed about the
transmission of HPV and HPV-related health consequences for men. My participants’ lack of perceived
risk for transmitting HPV; inaccurate knowledge about HPV transmission, prevention, and consequences
for male partners; and low self-efficacy for preventing the spread of HPV all impacted their decisions
about disclosure and sex behavior post diagnosis. Based on my research, I recommend that practitioners
discuss transmission, prevention methods, and the potential consequences of putting their partners at
risk. Individuals with HPV will not be able to prevent the continued spread of this highly prevalent STI
unless they are well informed about transmission and prevention, perceive themselves to be at risk for
re-infection or for infecting others, are motivated to use prevention methods, and feel capable of sexual
communication and condom negotiation with their partners.
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5

CONCLUSION

In this study, I used semi-structured interviews to uncover the lived experiences of individuals
with HPV. This method, compared to past HPV scholarship which heavily relied on survey research,
fostered discussion of actual experiences related to living with HPV, specifically knowledge, stigma,
disclosure, and sexual behavior. I sought to discover (1) whether individuals diagnosed with HPV were
knowledgeable about the infection prior to and after diagnosis, (2) how those diagnosed with HPV felt
about themselves after diagnosis and how their knowledge of HPV influenced these feelings, (3) why
they decided whether or not to disclose their status to family, friends, and sexual partners, and (4) how
HPV status influenced my participants’ sex life and use of STI prevention methods.
As a whole, my dissertation highlights how patient-provider interaction surrounding HPV
diagnosis greatly impacts individuals’ emotions, disclosure, and sexual behavior post diagnosis, in
addition to their general knowledge of the STI. Unsympathetic, impersonal, uninformative patientprovider interactions often led my participants to negatively view their status, feel shame, internalize
stigma, be misinformed on HPV transmission, withhold their status, and participate in unprotected sex
with their at-risk partners.
Despite the high prevalence of HPV, health literacy and basic knowledge about it remain
relatively low. Health literacy is positively associated with level of education, however, even among my
participants, who represented a highly educated portion of the population, HPV knowledge prediagnosis was low. Pre-diagnosis, many of my participants were uninformed about HPV prevalence,
transmission, and cancer facts. After diagnosis, participants often remained unaware of HPV’s skin-toskin transmission, clearance, and dormancy, thus demonstrating a continued low HPV health literacy.
An HPV diagnosis, similar to other STI diagnoses, often causes concern and anxiety. The majority
of my participants experienced feeling anxious, scared, or stressed when they were first diagnosed with
HPV. Many also expressed surprise and shame over their positive status. All participants who received
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word about their diagnosis from a nurse rather than their primary doctor, or who had an experience
where their clinical staff assumed their status was already known, recalled these negative emotions.
Very few of my participants mentioned feeling supported and having their worries assuaged by their
doctors.
Women with HPV possess a character stigma because they deviate from societal norms of
female chastity and purity. They can be viewed as promiscuous, irresponsible, and unclean. A majority
of my participants felt stigma related to their positive status. Many assumed that others judged them
based on the fact that HPV is an STI and thus, indicated they were not sexually responsible. Others
believed they were facing stigma because of the type of cancer they developed from HPV – anal cancer,
which they knew others were quick to pass judgement on. Many participants internalized this stigma
and felt shameful about their diagnosis and blamed themselves for their status. Some of my
participants, however, did not experience stigma related to their status, but realized that others with
HPV may face judgment from larger society.
Individuals with a hidden, discreditable stigma must decide who to tell or not tell about their
condition. Some may choose to disclose their character stigma to friends, family, or partners for
support. Others may decide to hide their status because of internalized shame and embarrassment.
Almost all of my participants disclosed their HPV status to someone in their life. Some participants who
felt stigma sought support or advice from friends who had previously experienced HPV themselves. Even
individuals who felt little to no stigma often disclosed to gather the same information. Many of these
individuals (both those that felt stigma and those that did not), in turn, were open about disclosing to
others who were newly diagnosed and wanting information or advice. Some of my participants withheld
their status from specific individuals in their life. They used this form of stigma management, selective
disclosure, because they knew they would face judgement from those people. Even some participants
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who felt little to no stigma attached to their status chose to selectively disclose by only mentioning their
treatments and not the fact that they were HPV related.
My participants had a variety of HPV types and stages of cervical dysplasia. Some individuals had
low-risk, asymptomatic HPV strains that posed little to no risk to their sexual partners. Many others,
however, had high-risk strains or mild to severe dysplasia caused by HPV. Transmitting these types of
HPV to sexual partners posed risks to them, depending on the specific strain of HPV - which most
participants did not know. These high-risk HPV strains could also be consequential for male partners’
future female partners. Although a high-risk strain may have cleared from my participants’ bodies, they
could become re-infected after treatment if they have already transmitted it to their current partner. A
few individuals had anogenital warts caused by HPV, which were easy to transmit to one’s partner
through sexual intercourse or skin-to-skin contact. Others did not know what type of HPV or cervical
dysplasia they had at the time of interview and without this knowledge, these individuals were unaware
of the potential risk they may have been causing their partners or their partners’ future partners.
Secondary STI prevention methods, which prevent transmission from a positive individual to
their partner, are more likely to be used if individuals are informed about transmission and prevention
techniques, motivated to practice preventive behaviors, perceive themselves and others to be at risk,
and are confident in their ability to perform prevention behaviors. The majority of my participants did
not disclose their HPV status to one or more of their at-risk sexual partners. Some did not disclose
because they felt it was a difficult conversation they did not want to initiate because of fear their
partner would reject them, embarrassment about their status, or a disinterest in admitting to their
infidelity. The majority of my participants, however, did not disclose their status to sexual partners
because they did not believe they were putting their male partners at risk. Many assumed their partners
already had HPV or saw no point in disclosing to male partners that could not get tested. Others
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assumed they were not putting their partners at risk because they were using condoms most of the time
or admitted that they would disclose if it were an STI they considered to be more serious.
None of my participants, however, used all barrier methods during male-female sexual
activities. Many used condoms on occasion, but none used dental dams with their male partners to
prevent transmission through oral sex. Some participants felt that their diagnosis was a catalyst for
participating in safer sex. Others, however, did not use condoms consistently and this was more often
true for those in monogamous relationships. A few participants reasoned that they were abstaining or
having sex less frequently as a means of protecting their partner. Most who were having less frequent
sex post-diagnosis, however, were doing so because sex had become painful after their HPV treatments.
The HPV vaccine reduces one’s risk for infection and thus prevents the spread of disease,
however, it is recommended for younger men and women and not covered by insurance past the age of
26. Most of my participants were not vaccinated because the vaccine was not available to them prediagnoses or they were unaware of the vaccine before being diagnosed with HPV or reaching the
insurance cut-off age. Many of my participants could have opted to pay out-of-pocket for the vaccine
past the age of 26 or post-diagnosis. Research suggests that previously infected individuals may benefit
from vaccination by increasing antibodies and thus helping individuals clear HPV more quickly and by
preventing re-infection. This was information that most of my participants were unaware of at the time
of interview. Without this information, they were unable to utilize this method to prevent their own
infection, transmission to their sex partners, or potential re-infection.
Many of my participants felt incapable of preventing the spread of HPV. This low self-efficacy
existed even if they knew how easily it was transmitted and sometimes was rooted in this knowledge.
Few understood that the most effective way to prevent transmission was through multiple barrier
methods, and even fewer were motivated to start using these prevention methods after diagnosis.
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Many of my participants saw HPV as an inescapable consequence of being sexually active, despite being
shocked and ashamed when they were diagnosed with it.
Participants’ low HPV health literacy, high levels of anxiety at time of diagnosis, continued
stigma, non-disclosure, and risky sexual behavior are related to sexual education, practitioner
messaging, and social norms around HPV. A substantial portion of the American population that is at risk
for acquiring and transmitting HPV is unaware of many aspects of the infection. Sexual education
programs should include curriculum on HPV related to the vaccine, transmission, dormancy, clearance,
cancer, and prevention methods. Decades of research demonstrate that people are dissatisfied with
how their doctors handle HPV diagnosing. Medical practitioners should strongly consider having a faceto-face conversation with their patients when providing a positive HPV diagnosis and make sure their
patients are fully informed about key aspects of the disease, such as prevalence, transmission,
dormancy, clearance, and how, specifically, it is linked to cancer. To prevent the continued spread of
high-risk HPV, normative behaviors around sex must change. Prevention programs should focus on
heightening the knowledge about and acceptance of alternative barrier methods to STIs. In addition to
increasing consistent condom use before penetrative sex in order to decrease transmission through
skin-to-skin contact, prevention efforts should aim at increasing the use of dental dams to prevent the
high-risk HPV through oral transmission.
My small exploratory study brought to light many unknowns that still surround HPV among
those infected. Past HPV research often relied on survey methods that did not provide rich detail about
experiences of those who lived with HPV. Few qualitative studies before this one were conducted since
the HPV vaccine was routinely recommended in the United States. I analyzed how routine vaccination
and subsequent increased awareness of HPV in the general public impacted by participants. Although I
sought to reveal the stories of a diverse sample based on ethnicity, race, and educational attainment
level, my sample was more homogeneous than initially intended. Future research should focus on how
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HPV knowledge varies among racial and ethnically diverse populations and how that knowledge impacts
stigma, disclosure, and sexual behavior among those groups. A few of my participants were vaccinated
before testing positive for HPV. Future research should focus on this small, but interesting group of
individuals living with HPV to better understand their lived experience and attitudes toward the vaccine.
My research shed light on how HPV impacted individual’s status disclosure and sexual behavior with
their partners. Future, large-scale, quantitative research can analyze how these aspects of safe and risky
sex differed among those who had low-risk HPV compared to high-risk HPV. Findings from such research
could pave the way for new prevention efforts that aim at stopping the spread of high-risk HPV strains
that are associated with most cervical, vaginal, vulvar, penile, anal, and throat cancer cases in American
men and women.
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APPENDIX: DEMOGRAPHICS
#

Pseudonym

Age at Interview

Age at

Strain/

Diagnosis

Dysplasia

Vaccinated

Childhood

Childhood

Educational

Job

Residence

Family

Attainment

Industry

Race

Structure
1

Andrea

39

26

Unknown

No

level of

United

Two-parent

Kingdom

Relationship

Gender

Sexual

Residence at

Status at

Identity

Orientation

Interview

Woman

Heterosexual

Northeastern

Interview
Bachelor’s

Arts

White

Degree

Married,
monogamous

US

dysplasia
2

Jessie

38

31

Unknown

No

level of

Southeastern

Two-parent

PhD

Law

White

US

Married,

Gender

monogamous

Queer

Married,

Woman

Lesbian

Canada

Heterosexual

Southeastern

dysplasia
3

Summer

32

24

Level 3

No

dysplasia
4

Alicia

5

Whitney

n/a

n/a

47

45

Southeastern

Two-parent

Master’s Degree

Law

White

US

monogamous

US

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

Low-risk

No

Northeastern

Two-parent

PhD

Health

White

Single

Woman

Bisexual

Western US

Northeastern

Divorced,

Bachelor’s

Business

White

Committed

Woman

Bisexual

Northeastern

US

lived with

Degree

Admin.

US
6

Amber

2

25

6

Unknown

Yes, age 16

level of
dysplasia

mother

7

Colleen

47

38

Low-risk

No

8

Leah

32

22

Level 3 or 4

No

dysplasia
9

Erica

27

26

Relationship,

Southeastern

Divorced, no

US

stepparent

Southeastern

Two-parent

monogamous
Master’s Degree

Health

White

Single

Woman

Heterosexual

Master’s Degree

Student

White

Married,

Woman

Heterosexual

Yes, post

Southeastern

level of

diagnosis

US

monogamous
Two-parent

Graduate

Law

White

Student

Committed

Southeastern
US

Woman

Heterosexual

Relationship,

dysplasia

Southeastern
US

monogamous

10

Kendra

22

22

Low-risk

Yes, age 12

11

Madison

n/a

n/a

n/a

n/a

Southeastern

Two-parent

n/a

n/a

12

Kaylee

27

26

Severe

Yes, age 19

Southeastern

Two-parent

US

dysplasia

Southeastern
US

US

Unknown

US

US

Undergraduate

Student

Black

Single

Woman

Heterosexual

n/a

n/a

n/a

n/a

n/a

n/a

n/a

GED

Arts

Black

Committed

Woman

Heterosexual

Southeastern

Student

Southeastern
US

Relationship,

US

113

(level 4)
13

Theresa

62

60

Anal cancer

monogamous
Yes, post

Canada

diagnosis

14

Carla

35

32

High-risk

Yes, age 25

Southeastern

Divorced,

Master’s Degree

Education

White

Committed

lived with

Relationship,

father

monogamous

Two-parent

US

Bachelor’s

Marketing

White

Committed

Degree

Woman

Heterosexual

Canada

Woman

Heterosexual

Southeastern

Relationship,

US

monogamous
15

16

Leslie

Candace

30

31

22

19

Mild

Yes, post

Southeastern

dysplasia

diagnosis

US

Unknown

No

Midwestern US

Two-parent

Master’s Degree

Health

White

Single

Woman

Heterosexual

Southeastern
US

Two-parent

Master’s Degree

Health

Black

Single

Woman

Heterosexual

level of

Southeastern
US

dysplasia
17

Tiffany

39

31

Unknown

No

Midwestern US

level of

Single

Some College

Health

Black

Single

Woman

Heterosexual

mother

Southeastern
US

dysplasia
18

Ava

23

22

warts

No

Midwestern US

Two-parent

Bachelor’s

Education

White

Committed

Degree

Woman

Heterosexual

Relationship,

Southwestern
US

monogamous
19

Emily

25

19

warts

No

Southeastern

Divorced,

US

step families

Master’s Degree

Arts

Biracial

Single

Woman

Heterosexual

(White/

Southeastern
US

I
ndian)
20

21

McKenzie

Riley

50

33

25

20

Low-risk

Level 3

No

No

dysplasia

Southeastern

Single

US

mother

Southeastern

Two-parent

US

Master’s Degree

Health

White

Married, non-

Woman

Bisexual

Western US

Woman

Bisexual

Southeastern

monogamous
Bachelor’s

Health

White

Degree

Committed
Relationship,

US

monogamous
22

Katherine

59

28

Anal cancer

No

Northeastern

Two-parent

US
23

Ashley

35

19

warts

No

Bachelor’s

Engineer

White

Single

Woman

Heterosexual

Degree

Northeastern

Divorced,

US

step families

Master’s Degree

Northeastern
US

Education

White

Committed
Relationship,

Woman

Heterosexual

Southeastern
US

114

monogamous
24

Janelle

43

43

Low-risk

No

25

Phoebe

30

20

Mild

No

Northeastern

Two-parent

Master’s Degree

Education

Black

Single

Woman

Heterosexual

Two-parent

Master’s Degree

Health

White

Single

Woman

Heterosexual

US

dysplasia

Northeastern
US

Southeastern
US
Southeastern
US

